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 Overview of Invasive Meningococcal Disease 
   Neisseria meningitidis or meningococcus is a gram negative diplococcus. At 
least 13 serogroups are known. The most common of these, which cause the 
majority of clinical disease, are A, B, C, Y, and W-135.5,6  Humans are the only 
host of N.meningitidis.7 Transmission occurs via contact with large aerosol 
droplets or contact with respiratory tract secretions. Examples of contact 
include kissing, sharing drinks or cigarettes, mouth-to-mouth resuscitation, and 
intubation.6 
    A carrier state occurs in 10% or more of the population.8 This may increase 
to 60-80% in closed populations.9 Carriers are most frequently colonized in the 
nasopharynx with low or non-pathogenic strains of N. meningitidis or a related 
non-pathogenic bacteria, N. lactamica.5,8 By age 30, the majority of the 
population has had 10 different episodes of carriage.8 Carriage is an immune-
inducing event. Cross-reactivity of antibodies occurs.10 By adulthood, the 
majority of people have formed antibodies to A, B, C, Y, and W-135.11 Carriage 
is highest in adolescents and lowest in young children.8 Despite this relatively 
high carrier state, less than 1% of colonized organisms invade.12 
    Clinical syndromes caused by N. meningitidis include septicemia, meningitis, 
bacteremia, pneumonia, and other infections of normally sterile body fluid, 
such as septic arthritis, conjunctivitis, and pericarditis.5 In septicemia, patients 
often present with hypotension, diffuse petechiae, and may develop 
disseminated intravascular coagulation and purpura fulminans. In meningitis, 
the organism crosses the blood-brain barrier. This occurs in 50% of the cases 
and occurs 24-48 hours after the bacteria invades the bloodstream.9,12 Cases of 
bacteremia often present with non-specific symptoms and meningococcus may 
not be suspected.2 Pneumonia occurs in up to 15% of the cases.12 The 
incubation period of the organism is generally 2-4 days but ranges from 1-10 
days. A patient remains infectious as long as N. meningitidis remains in the 
nasopharynx and until 24 hours after receiving appropriate antibiotics.13 
     High risk groups include: 
• College freshmen living in dormitories 
• Military recruits 
• Microbiologists routinely exposed to N. meningitidis 
• Those with terminal complement component deficiencies 
• Those with functional/anatomic asplenia 
• Travelers to hyperendemic or epidemic areas. Examples include 
Sub-Saharan Africa, “the meningitis belt” and Saudi Arabia during 
the pilgrimage to Mecca.1,10 
   Risk factors for disease include antecedent viral infection, crowding, chronic 
disease, including hepatic disease, multiple myeloma, and systemic lupus 
erythematous, and active and passive smoking. Black race and lower 
socioeconomic status are felt to be risk markers for IMD.1,10 
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Epidemiology in the United States 
 
Overall 
     Approximately 1,400-2,800 cases/year occur in the US. The rate of disease is 
0.5-1.1/100,000 population.1 This range reflects the cyclical incidence of the 
disease.14 98% of cases are sporadic. Outbreaks are uncommon.11 CFR is high, 
10-14%, and may be as high as 20% in the adolescent population.1,15 Morbidity 
in survivors occurs in 11-19% and includes limb loss, neurologic disability, and 
hearing loss.1 IMD follows a seasonal pattern with the majority of cases in the 
winter and early spring months.16 
 
 Distribution by Serogroup 
     In the US, serogroups B, C, and Y each cause about 1/3rd of cases. In the 
infant population, ≥50% of cases is caused by serogroup B. For ages ≥ 11, 75% 
is caused by C, Y, and W-135, vaccine-preventable serogroups.1 A higher 
proportion of serogroup Y IMD occurs in the elderly.11 Serogroup A rarely causes 
disease in the US.5  
     Internationally, serogroup A is significant in Africa and Asia. Serogroup B is 
significant in Europe, South America, New Zealand, and Australia.9 
     Antigenic shift provides a possible explanation for the change in serogroup 
distribution over time. Dramatic changes were noticed in the 1990’s. Cases 
caused by serogroup Y increased from 2% in 1989-1991 to 37% in 1997-2002. 
Additionally, disease rate increased in the 15-24 year old population with 
approximately 50% caused by serogroup C.  In antigenic shift, the bacteria 
genetically changes so that a new virulent strain of the serogroup forms and 
evades established host immunity.14 
  
 Distribution by Age 
     As can be seen in FIGURE 1, IMD has two main peaks by age. The greatest 
rate of IMD occurs in the <1year old population. A second peak occurs in late 
adolescence.15 Some possible explanations for the <1 year old peak are the loss 
of maternal antibody protection at 3 months and the low carriage state. For the 
late adolescent population, crowding, smoking, and the high carriage state 
contribute to the peak in incidence. The carrier state provides exposure to 
N.meningitidis and antibody development, but also provides exposure to virulent 
strains and the risk of invasive disease.5,8 
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FIGURE 1: Rate of Meningococcal Disease by age-US, 1991-2002                             
Centers for Disease Prevention and Control. Prevention and Control of Meningococcal Disease: 
Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2005;54(RR-7). 
 
    
 
    Although the greatest rate of disease is in the <1 year old population, the 
greatest burden of disease (% of cases) is in the 25-64 year old population as 
can be seen in FIGURE 2.15 
 
 
 
FIGURE 2: Burden of disease (percentage of cases) and rates of 
invasive meningococcal disease (all serogroups) in the United States, 
1991-2002, according to age (CDC, Active Bacterial Core surveillance) 
Committee on Infectious Diseases, Pediatrics 2005;116:496-505 
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Distribution by Race/Ethnicity     
      Blacks are at a higher risk of IMD although this is felt to be a risk marker. 
(due to environmental factors rather than a genetic predisposition to developing 
the disease.)1 
 
Distribution by Gender 
      Males account for 51-55% of cases.9,17 
 
Distribution by Syndrome 
   Meningitis, defined as meningitis with or without meningococcemia is more 
common than bacteremia alone. The death rate is higher with 
meningococcemia.17-19 
 
 
Surveillance in the United States 
       Surveillance on a national level is accomplished in two ways. States send 
information to the CDC once a week via the National Electronic 
Telecommunications System for Surveillance (NETSS) on nationally reportable 
diseases which includes IMD. Provisional data is published weekly in MMWR. At 
the end of the year, the compiled data is corrected and finalized. This report is 
published in MMWR as a Summary of Notifiable Diseases for that year. A 
limitation of this sytem is that reporting is voluntary.20 Active Bacterial Core 
surveillance (ABCs) is an active surveillance system for 6 pathogens including N. 
meningitidis. There are 10 sites in the US representing a population of over 38 
million persons. For ABCs cases, additional demographic information is obtained 
on cases, additional laboratory studies are performed on samples, isolates are 
sent to the CDC for additional testing, and laboratories are both contacted and 
audited regularly.21 
 
 
Treatment 
     Intravenous (IV) Penicillin G is the treatment of choice.9 Alternatives are IV 
Ceftriaxone and Ampicillin. IV Chloramphenicol is a choice for penicillin allergic 
patients.13 Except for the third-generation cephalosporins, the IV treatment 
options do not eradicate nasopharyngeal carriage. Patients not receiving an IV 
third-generation cephalosporin for the acute disease need one of the 
chemoprophylactic antibiotics prior to hospital discharge to eradicate 
nasopharyngeal carriage.24 Antibiotic resistance to Penicillin has not been a 
problem in the US with N. meningitidis.9 
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Prevention 
A. Vaccination 
      Currently there are two meningococcal vaccines available in the US, the 
meningococcal polysaccharide vaccine (MPSV4 or Menomune) and the 
meningococcal conjugate vaccine (MCV4 or Menactra). Both of these vaccines 
are tetravalent and contain antigens to serogroups A,C,Y, and W-135. There is 
no serogroup B coverage in these vaccines.11 
     The meningococcal polysaccharide vaccine was licensed in 1981 for use in 
those ≥2 years of age. This vaccine has been used in all military recruits since 
1982. Limitations of this vaccine include a short duration of protection, booster 
may lead to a diminished antibody response, lack of interruption of the carrier 
state, and lack of herd immunity.1,11 
     The meningococcal conjugate vaccine was licensed in January 2005 for use in 
those 11-55 years of age. The advantages of this vaccine include a longer 
duration of protection and booster leads to a rise in antibodies. Assumed 
advantages, based on experience with other conjugate vaccines such as that for 
H.influenza and S.pneumoniae, include a reduction in the carrier state and 
development of herd immunity.  
          In the US, the Advisory Committee on Immunization Practices of the CDC 
has recommended routine vaccination with the meningococcal conjugate vaccine 
for 11-12 year olds at their pre-adolescent physician visit; catch-up at age 15 if 
vaccine not yet received; and to those in high risks groups, which includes 
entering college students who plan to live in dormitories.1 Groups that have 
endorsed these recommendations include the American Academy of Pediatrics 
and the American Academy of Family Physicians.15,32  
     
B. Chemoprophylaxis 
     Chemoprophylaxis is an important component of prevention. Contacts of     
IMD cases who should receive prophylaxis include household contacts, child-care 
center contacts, and those who have had prolonged and/or intimate contact with 
the patient.1  Generally, school and work contacts are not included unless the 
contact has been close. Administration of chemoprophylaxis is ideal within 24 
hours. Benefit is still achieved up to 2 weeks, however, the benefit decreases as 
time elapses from the exposure. After 2 weeks, the benefit is not appreciable 
and hence is not recommended. The current choices for prophylaxis are 
• Rifampin for adults and children, oral dose twice a day for 2 days 
• Ciprofloxacin for adults, one time oral dose 
• Ceftriaxone for adults and children, one time intramuscular dose 11 
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Prevention Mandates for US Colleges and Universities 
 
     As shown in FIGURE 3, mandates for meningococcal prevention for college 
students differ from state to state. 11 states currently require proof of 
vaccination or waiver for their colleges and universities. 24 states require 
education. The remaining 15, which includes Arizona, do not have 
requirements.33  
 
FIGURE 3 
 
Source=Immunization Action Coalition (2006). Available from http://www.immunize.org/laws/meninmap.pdf 
 
 
 
Surveillance in Maricopa County 
 
      Reporting is required in Arizona under the Arizona Administrative Code. 
Reporting requirements differ by reporting group. For health care providers, a 
report must be submitted to the local health department within 24 hours for a 
case or suspect case. For laboratories, a report on a positive lab test must be 
submitted within 24 hours to the Arizona Department of Health Services and 
isolates must be submitted to the Arizona State Public Health Laboratory. 
Violation of this reporting is a Class III Misdemeanor.22 
    The case definition of a confirmed case of IMD is a clinically compatible case 
with culture confirmation of N. meningitidis from a normally sterile site. A 
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probable case is a clinically compatible case with a positive PCR or positive N. 
meningitidis antigen. A suspect case is presence of purpura fulminans without a 
positive blood culture or clinical compatibility with gram negative diplococci on 
gram stain of a sample from a normally sterile site. 23 
     Data from the Communicable Disease Report form (CDR) submitted to 
MCDPH is maintained in an electronic CDR database. Case investigation is 
performed by a community health nurse investigator using the National Bacterial 
Meningitis and Bacteremia Case Report form (long form). The data from the long 
forms is transferred to an Excel spreadsheet and maintained electronically. This 
data is available from G:\EPI\New Surveillance\Communicable Diseases\Specific 
Diseases\Bacterial meningitis\Forms        
 
 
 
Epidemiologic Trends in Maricopa County 2000-2006 
 
Overall 
     During 1/1/2000-6/30/2006, 113 confirmed and probable in-county cases of 
IMD were reported to MCDPH. 12 deaths occurred in this group. (See TABLE 1) 
 
 
 
TABLE 1, Invasive Meningococcal Disease in Maricopa County        
2000-2006* 
 2000 2001 2002 2003 2004 2005 2006 Total 
# of 
Cases 
28 13 
 
20 17 11 19 5 113 
 
Rate 
0.90 
 
0.41 0.61 0.50 0.31 0.52 0.22†  
# of 
Deaths 
3 0 5 1 0 1 2 12 
Case 
Fatality 
Rate 
11% 0% 25% 6% 0% 5% 40% 11% 
*Year 2006 through 6/30/2006                                               †Annualized as of 6/30/2006 
Rates per 100,000 population US Census estimates 
 
 
 
     Rate of disease was at a high of 0.90 in 2000 and slowly trended down over 
time to a low in 2006 of 0.22 (annualized). Median rate was 0.5. Annualized 
average rate was 0.47. At no time during the study period was the rate             
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≥ 1/100,000 population. The overall case-fatality rate was 11% which was 
similar to that previously discussed from the literature. 
 
 
     FIGURE 3 provides an overall look at the rate of IMD in MC from 1983-2006. 
An outbreak occurred in 1993.  
 
 
 
FIGURE 3, Invasive Meningococcal Disease in Maricopa County, Rates 
by Year on Onset, 1983-2006* 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Year 2006 annualized as of 6/30/2006                           All MC data from MCDPH, Office of   
Rates per 100,000 population US Census estimates             Epidemiology 
 
 
 
     FIGURE 4 shows the rates of IMD in the US and MC from 1983-2006. The 
rate in MC from 2000-2006 was similar to the US rate during this same time 
period. In both cases, the rate slowly trended down over time and was 
<1/100,000 population. 
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FIGURE 4, Invasive Meningococcal Disease in the US and Maricopa 
County, Rates by Year of Onset 2000-2006* 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Year 2006 annualized as of 6/30/2006                           All MC data from MCDPH. Office of   
Rates per 100,000 population US Census estimates             Epidemiology 
Raw numbers for US rate calculation obtained from CDC. Summary of Notifiable Diseases, US, 2000-2004. 
MMWR 2000;49(53); MMWR 2001;50(53);MMWR 2002;51(53);MMWR 2003;52(54);MMWR2004;53(53)2004 
& CDC. Notifiable  Diseases/Deaths in Selected Cities Weekly Information. MMWR 2006;54(52);1320-1330 
 
 
 
Seasonality 
     The distribution of cases by month of onset in MC followed a seasonal pattern 
similar to what was discussed earlier from the literature. A higher percentage of 
cases were seen in the winter and early spring months.(See FIGURE 5) 
 
 
FIGURE 5, Invasive Meningococcal Disease in Maricopa County, 
Percentage Distribution by Month of Onset 2000-2005 
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Distribution by Serogroup 
    The proportions of IMD cases by serogroup in MC differed from that reported 
in the literature for the US.( See FIGURE 6) Unlike the US where serogroups B,C, 
and Y each cause 1/3rd of cases, in MC B caused 26%; C caused 18%; and Y 
caused 20%. 15% of MC cases were unknowns and 17% were Not Groupable. 
Unknowns were samples that were not sent to the AZ State Lab for serogrouping 
or cultures that did not grow because the patient received antibiotics prior to 
obtaining the cultures. Not Groupables are capsule-deficient samples that cannot 
be serogrouped due to their lack of capsule. Not Groupable samples that cause 
disease are either genetically B, C, or Y but capsule-deficient or another 
unidentifiable serogroup that is capsule-deficient.34 The effect of these two 
groups on the MC data is unclear. 
 
 
 
 
FIGURE 6, Invasive Meningococcal Disease in Maricopa County by 
Serogroup, 2000-2005 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Others=Serogroups A & W-13 
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     Comparison of the proportion of IMD cases by serogroup in MC to the US per 
ABCs data showed MC with a lower proportion of serogroup B cases and a higher 
proportion of Other cases, those due to W-135 or Not Groupables. (See FIGURES 
7a & 7b) Only 3 cases of W-135 occurred in MC between 2000-2005, so the 
Other category in MC was mainly Not Groupables.  
 
 
FIGURES 7a & 7b, Invasive Meningococcal Disease in the US and 
Maricopa County by Serogroup, 2000-2005 
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2000-2005 MC
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             US data per Active Bacterial Core Surveillance (ABCs) Report Emerging Infections Program Network     
          Neisseria meningitidis, 2000-2005-provisional 
            Unknowns diistributed among knowns 
            Other=Serogroup  W-135 & Not Groupables 
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    Most notable when looking at proportion of serogroup for IMD cases in MC 
was the consistency of the proportion of vaccine-preventable cases over time. 
Proportion of vaccine-preventable disease was approximately 40-45% each year 
except in 2001. Of note also is that the proportion of unknown cases seemed to 
be increasing. (See FIGURE 8) 
 
FIGURE 8, Invasive Meningococcal Disease in Maricopa County by 
Serogroup, 2000-2005 
 
 
 
 
 
 
 
 
 
 
 
 
 
Vaccine Preventable=Groups A,C,Y,W-135 
 
Distribution by Age 
      Most notable in the distribution of IMD by age in MC was the rate for the 0-4 
year old population. This rate trended down over time. (See FIGURE 9). By 
2004-2005, all age groups had fairly similar rates of disease.    
 
FIGURE 9, Invasive Meningococcal Disease in Maricopa County by Age, 
2000-2005 
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     Comparison of the distribution of IMD for the 0-4 year old population 
between MC and the US, using ABCs data (FIGURE 10), showed that both were 
trending down over time. By 2004, however, the rate in the 0-4 year old 
population in MC seemed to be lower than that in the US. 
 
 
Figure 10, Invasive Meningococcal Disease in US and Maricopa County, 
Age 0-4 Years, 2000-2005 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Rates per 100,000 US Census population estimates. 
Raw numbers for US  rate calculation obtained from CDC. Summary of Notifiable Diseases, US, 2000-2004. 
MMWR 2000;49(53); MMWR 2001;50(53);MMWR 2002;51(53);MMWR 2003;52(54);MMWR 
2004;53(53)2004 
 
 
Distribution by Age and Serogroup 
     Comparison of the serogroup distribution in the <1 year old populations in 
MC to that in the US per ABCs data (See FIGURES 11a & 11b), showed a lower 
proportion of serogroup B disease and a higher proportion of Other disease in 
MC. No cases of W-135 occurred in the <1 year old population in MC during 
2000-2005 so the Other category in MC was entirely Not Groupables. The 
proportion of serogroup B cases in the US data seemed consistent with that 
discussed in the literature, ≥50%. MC’s proportion was lower than this at 37%. 
The highest proportion of cases in MC in the <1 year old population was Not 
Groupables.  
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FIGURE 11a & 11b, Invasive Meningococcal Disease in the US & 
Maricopa County, Age < 1 year by Serogroup,  
2000-2005 
2000-2005 US
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2000-2005 MC
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21%
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Other n=8
 
US data per Active Bacterial Core Surveillance (ABCs) Report Emerging Infections Program Network 
Neisseria meningitidis, 2000-2005-provisional 
Unknowns distributed among knowns 
Other=W-135 & Not Groupables 
 
 
     IMD in the <1 year old population in MC has decreased over time. (See 
FIGURE 12) As discussed earlier, per the literature the <1 year old population 
has the highest overall rate of IMD. In MC, there have no cases in this age group 
since 2004 and no cases of serogroup B disease since 2002.  
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FIGURE 12, Invasive Meningococcal Disease in Maricopa County,                
Age < 1 year by Serogroup, 2000-2005 
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      Evaluation of distribution of IMD by age and serogroup in MC showed that 
the proportion of C, Y, and W-135 was less than the 75% quoted in the literature 
for those ≥11 years. (See FIGURE 13) The effect the Unknown and Not 
Groupable categories have on this is unclear. In the elderly, Y caused the 
greatest proportion of cases which is consistent with that mentioned earlier from 
the literature. 
 
FIGURE 13, Distribution of Invasive Meningococcal Disease in Maricopa 
County by Age & Serogroup, 2000-2005 
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     The proportion of vaccine-preventable disease in MC was greatest in the 10-
24 year old and 25-64 year old populations. (See FIGURE 14) 
 
FIGURE 14, Vaccine-Preventable* Invasive Meningococcal Disease in 
Maricopa County by Age 2000-2005 
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            *Vaccine Preventable=A,C,Y,W-135 
 
Distribution by Race/Ethnicity 
     The rate of IMD in the Hispanic population in MC trended down during the 
study period. (See FIGURE 15) By 2004-2005, the rates in all 3 race/ethnicity 
categories were very similar.  
 
FIGURE 15, Invasive Meningococcal Disease in Maricopa County by 
Race/Ethnicity, 2000-2005 
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Distribution by Race/Ethnicity and Serogroup 
     During the study period, the non-white populations had higher rates for 
serogroup B disease and the Hispanic population had the highest rate for 
vaccine-preventable disease. (See FIGURE 16) 
 
FIGURE 16, Invasive Meningococcal Disease in Maricopa County by 
Race/Ethnicity and Serogroup,  
2000-2005 
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Distribution by Gender 
     Rates of IMD in MC for male and females during the study years were very 
similar. (See FIGURE 17) 
 
FIGURE 17, Invasive Meningococcal Disease in Maricopa County by 
Gender, 2000-2005 
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Distribution by Syndrome 
     In MC, the highest proportion of IMD by syndrome was due to cases of 
bacteremia alone, closely followed by meningitis. A very low proportion of cases 
was caused by other syndromes. (See FIGURE 18) In the US ABCs data and in 
the literature, the highest proportion of cases was due to meningitis. 
 
 
 
FIGURE 18, Invasive Meningococcal Disease in Maricopa County by 
Syndrome, 2000-2005 
 
 
 
 
 
 
 
 
 
 
 
 
US data per Active Bacterial Core Surveillance (ABCs) Report Emerging Infections Program Network 
Neisseria meningitidis, 2000-2005-provisional 
Meningitis=meningitis +/-meningococcemia 
 
 
Geographic Distribution 
     No apparent clusters were seen for IMD in MC during the study period. (See 
MAP 1) For 2002, 6 cases did occur in census tracts of relatively close proximity 
along a north to south corridor in Phoenix. 
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MAP 1: Invasive Meningococcal Disease in Maricopa County 
by Census Tracts 2000-2006 
 
 
14/113 cases (12%) not geocoded. 
Generated using ArcMap GIS software. 
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Statistical Analysis 
     Limited statistical analysis was performed on the data. Using SPSS, a logistic 
regression model was used to test for any statistically significant relationship 
between age, sex, serogroup. or syndrome and outcome; and between 
serogroup and age. No statistically significant associations were found.  
 
 
Reporting and Investigation in Maricopa County 
2005-2006 
 
    A subset of cases reported to MCDPH from 1/1/2005-6/30/2006 was analyzed. 
27 cases occurred during this period.  In approximately 50% of cases, IMD cases 
were reported to MCDPH 1-2 days after cultures were obtained. In the other 
50% of cases, report was made ≥3 days after cultures were obtained. (See 
FIGURE 19) As discussed earlier, health care providers are required to report a 
suspect or confirmed case of IMD within 24 hours.  
 
 
FIGURE 19, Time to Report Case* to Maricopa County Department of 
Public Health, 1/1/2005-6/30/2006 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Case=confirmed & probable, Maricopa County or out of state 
Time to report case=time from date of 1st culture to date of report 
 
 
     In 26 out of 27 cases in the subset of data analyzed, investigation at MCDPH 
was done on the same day as the report received. In one case, no information 
was provided in the record as to the date of investigation. (See FIGURE 20) 
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FIGURE 20, Time to Start Investigation at Maricopa County 
Department of Public Health after Report Received,                      
1/1/2005-6/30/2006 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     
 
 
     In the majority of cases, prophylaxis of contacts was done. (See FIGURE 21) 
In seven cases the record was unclear as to whether prophylaxis was done or 
not. 
 
FIGURE 21, Prophylaxis of Cases, 1/1/2005-6/30/2006 
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Conclusions 
 
     This study provides baseline epidemiologic trends of IMD in MC. The trends of 
particular interest include 
1. The lower proportion of serogroup B cases 
2. The higher proportion of Not Groupable cases 
3. The declining rate in the 0-4 year old population 
4. The lack of any cases in the <1 year old population since 2004 
5. The lack of any B cases in the <1 year old population since 2002  
6. The higher proportion of Bacteremia alone cases 
7. The sizeable proportion of vaccine-preventable disease  
8. The highest rate of vaccine-preventable disease in the Hispanic population 
 
     This study also provides useful information for MCDPH, Office of 
Epidemiology on reporting, investigating, and data completeness. Reporting of 
cases of IMD to MCDPH occurred ≥ 3 days in about 50% of the cases, despite a 
24 hour reporting mandate for cases or suspect cases. 
     Data on IMD in MC can be analyzed on a yearly basis using this study as a 
model. Future analyses can reassess the epidemiologic trends noted in this study 
and assess the effect of routine meningococcal vaccination in MC. Reassessment 
of the distribution of vaccine preventable disease by age will be important. If the 
conjugate vaccine interrupts the carrier state and if herd immunity is elicited, the 
proportion of vaccine preventable disease should decrease in both the 
immunized and not immunized populations. If immunity lasts long, over time 
older age groups should show a lower proportion of vaccine-preventable disease. 
      
 
Areas of Future Study & Action 
 Areas of further investigation and action should include  
1. The Not Groupable serogroup category. 
• Is there a lab cause for the higher proportion of Not Groupable 
cases in MC compared to the US ABCs data?  
• Is an unidentified serogroup causing disease in MC? 
• Could the AZ State Lab collaborate with the CDC to evaluate this? 
2. The higher rate of vaccine preventable disease in the Hispanic population. 
• Would GIS mapping of vaccine preventable disease in MC by 
race/ethnicity and serogroup provide useful information? 
• Are the cases grouped in similar areas where vaccination could be 
targeted?  
3. Late reporting of cases 
• Send a letter to health care providers in MC about the reporting 
requirements, the conjugate vaccine, and the importance of 
reporting to achieve early prophylaxis and thorough documentation 
of cases. 
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• Send a letter to laboratories in MC about the reporting 
requirements and reinforce the importance of sending isolates to 
the AZ State Lab for serogrouping so that the epidemiology of IMD 
in MC can be accurately understood.  
• A possible future internship project could be analysis of timeliness 
of reporting to MCDPH for various diseases, determination of 
barriers to timely reporting, and determination of methods for 
improvement. 
4. Colleges and Universities in MC 
• Contact in reference to meningococcal vaccination policies for 
entering students 
5. Documentation of meningococcal vaccination status 
• Routinely obtain this information as part of the case investigation 
• Obtain updated CDC National Bacterial Meningitis and Bacteremia 
Case Report form with fields for vaccination information when 
available (currently in draft stage per CDC) 
6. CDC 
• Follow-up with the CDC to discuss this report  
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 A. Cases & Deaths of Invasive Meningococcal Disease(IMD) in 
Maricopa County(MC) by Syndrome, 2000-2006, per year           
          
TABLE 1-Cases & Deaths of IMD in MC by Syndrome in 2000 
  Cases   Deaths  
Syndrome # % Rate* # % Rate† CFR 
Meningitis 7 25% 0.23 0 0% 0.00 0% 
Bacteremia 17 61% 0.55 3 100% 0.10 11% 
    Both 4 14% 0.13 0 0% 0.00 0% 
Other 0 0% 0.00 0 0% 0.00 0% 
Total 28 100% 0.90 3 100% 0.10 11% 
*†per 100000 population, estimates per US Census    
 
TABLE 1-Cases & Deaths of IMD in MC by Syndrome in 2001 
  Cases   Deaths  
Syndrome # % Rate* # % Rate† CFR 
Meningitis 3 23% 0.09 0 0% 0.00 0% 
Bacteremia 6 46% 0.19 0 0% 0.00 0% 
    Both 3 23% 0.09 0 0% 0.00 0% 
Other 1 8% 0.03 0 0% 0.00 0% 
Total 13 100% 0.41 0 0% 0.00 0% 
*†per 100000 population, estimates per US Census    
 
TABLE 1-Cases & Deaths of IMD in MC by Syndrome in 2002 
  Cases   Deaths  
Syndrome # % Rate* # % Rate† CFR 
Meningitis 8 40% 0.24 2 40% 0.06 10% 
Bacteremia 8 40% 0.24 1 20% 0.03 5% 
    Both 3 15% 0.09 2 40% 0.06 10% 
Other 1 5% 0.03 0 0% 0.00 0% 
Total 20 100% 0.61 5 100% 0.15 25% 
*†per 100000 population, estimates per US Census    
 
TABLE 1-Cases & Deaths of IMD in MC by Syndrome in 2003 
  Cases   Deaths  
Syndrome # % Rate* # % Rate† CFR 
Meningitis 4 24% 0.12 0 0% 0.00 0% 
Bacteremia 8 47% 0.24 1 100% 0.03 6% 
    Both 5 29% 0.15 0 0% 0.00 0% 
Other 0 0% 0.00 0 0% 0.00 0% 
Total 17 100% 0.50 1 100% 0.03 6% 
*†per 100000 population, estimates per US Census    
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TABLE 1-Cases & Deaths of IMD in MC by Syndrome in 2004 
  Cases   Deaths  
Syndrome # % Rate* # % Rate† CFR 
Meningitis 4 36% 0.11 0 0% 0.00 0% 
Bacteremia 5 45% 0.14 0 0% 0.00 0% 
    Both 1 9% 0.03 0 0% 0.00 0% 
Other 1 9% 0.03 0 0% 0.00 0% 
Total 11 100% 0.31 0 0% 0.00 0% 
*†per 100000 population, estimates per US Census    
 
TABLE 1-Cases & Deaths of IMD in MC by Syndrome in 2005 
  Cases   Deaths  
Syndrome # % Rate* # % Rate† CFR 
Meningitis 6 32% 0.17 0 0% 0.00 0% 
Bacteremia 10 53% 0.28 1 100% 0.03 5% 
    Both 3 16% 0.08 0 0% 0.00 0% 
Other 0 0% 0.00 0 0% 0.00 0% 
Total 19 100% 0.52 1 100% 0.03 5% 
*†per 100000 population, estimates per US Census    
 
TABLE 1-Cases & Deaths of IMD in MC by Syndrome in 2006, 1/1-6/30 
  Cases   Deaths   
Syndrome # % Rate  # %  Rate CFR  
Meningitis 2 40%   1 50%   20%  
Bacteremia 3 60%   1 50%   20%  
    Both 0 0%   0 0%   0%  
Other 0 0%   0 0%   0%  
Total 5 100%   2 100%   40%  
 
TABLE 1-Cases & Deaths of IMD in MC by Syndrome   
 1/1/2000-6/30/2006     
  Cases   Deaths  
Syndrome # % Rate # % Rate CFR 
Meningitis 34 30%   3 25%   3% 
Bacteremia 57 50%   7 58%   6% 
    Both 19 17%   2 17%   2% 
Other 3 3%   0 0%   0% 
Total 113 100%   12 100%   11% 
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B. Cases & Deaths of Invasive Meningococcal Disease(IMD) in 
Maricopa County(MC) by Race/Ethnicity, 2000-2006, per year 
 
TABLE 2-Cases & Deaths of IMD in MC by Race/Ethnicity in 2000  
   Cases   Deaths  
Race/Ethnicity # % Rate* # % Rate† CFR 
White  12 43% 0.58 2 67% 0.10 7% 
Hispanic  10 36% 1.32 1 33% 0.13 4% 
Black  3 11% 2.71 0 0% 0.00 0% 
Am Indian/Alaskan Native 2 7% 4.04 0 0% 0.00 0% 
Asian/Pacific Islander 1 4% 1.41 0 0% 0.00 0% 
Other  0 0% 0.00 0 0% 0.00 0% 
Total  28 100% 0.90 3 100% 0.10 11% 
§Combo B, A/A, A/PI, 
Other 6 21% 2.24 0 0% 0.00 0% 
*†per 100000 population, estimates per US Census     
§ Total of Black, Am Indian/Alaskan Native, Asian/Pacific Islander, and Other   
 
TABLE 2-Cases & Deaths of IMD in MC by Race/Ethnicity in 2001  
   Cases   Deaths  
Race/Ethnicity   # % Rate* # % Rate† CFR 
White  6 46% 0.29 0 0% 0.00 0% 
Hispanic  7 54% 0.86 0 0% 0.00 0% 
Black  0 0% 0.00 0 0% 0.00 0% 
Am Indian/Alaskan Native 0 0% 0.00 0 0% 0.00 0% 
Asian/Pacific Islander 0 0% 0.00 0 0% 0.00 0% 
Other  0 0% 0.00 0 0% 0.00 0% 
Total  13 100% 0.41 0 0% 0.00 0% 
§Combo B, A/A, A/PI, 
Other 0 0% 0.00 0 0% 0.00 0% 
*†per 100000 population, estimates per US Census     
§ Total of Black, Am Indian/Alaskan Native, Asian/Pacific Islander, and Other   
 
TABLE 2-Cases & Deaths of IMD in MC by Race/Ethnicity in 2002  
   Cases   Deaths   
Race/Ethnicity   # % Rate* # % Rate† CFR 
White  10 50% 0.47 2 40% 0.09 10% 
Hispanic  10 50% 1.15 3 60% 0.35 15% 
Black  0 0% 0.00 0 0% 0.00 0% 
Am Indian/Alaskan Native 0 0% 0.00 0 0% 0.00 0% 
Asian/Pacific Islander 0 0% 0.00 0 0% 0.00 0% 
Other  0 0% 0.00 0 0% 0.00 0% 
Total  20 100% 0.61 5 100% 0.15 25% 
§Combo B, A/A, A/PI, Other 0 0% 0.00 0 0% 0.00 0% 
*†per 100000 population, estimates per US Census 
§ Total of Black, Am Indian/Alaskan Native, Asian/Pacific Islander,  
and Other     
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TABLE 2-Cases & Deaths of IMD in MC by Race/Ethnicity in 2003  
   Cases   Deaths   
Race/Ethnicity   # % Rate* # % Rate† CFR 
White  8 47% 0.37 0 0% 0.00 0% 
Hispanic  7 41% 0.76 0 0% 0.00 0% 
Black  0 0% 0.00 0 0% 0.00 0% 
Am Indian/Alaskan Native 1 6% 1.81 1 100% 1.81 6% 
Asian/Pacific Islander 0 0% 0.00 0 0% 0.00 0% 
Other  1 6% 2.35 0 0% 0.00 0% 
Total  17 100% 0.50 1 100% 0.03 6% 
§Combo B, A/A, A/PI, 
Other 2 12% 0.65 1 100% 0.33 6% 
*†per 100000 population, estimates per US Census     
§ Total of Black, Am Indian/Alaskan Native, Asian/Pacific Islander, and Other   
 
TABLE 2-Cases & Deaths of IMD in MC by Race/Ethnicity in 2004  
   Cases   Deaths   
Race/Ethnicity   # % Rate* # % Rate† CFR 
White  8 73% 0.37 0 0% 0.00 0% 
Hispanic  2 18% 0.21 0 0% 0.00 0% 
Black  1 9% 0.76 0 0% 0.00 0% 
Am Indian/Alaskan Native 0 0% 0.00 0 0% 0.00 0% 
Asian/Pacific Islander 0 0% 0.00 0 0% 0.00 0% 
Other  0 0% 0.00 0 0% 0.00 0% 
Total  11 100% 0.31 0 0% 0.00 0% 
§Combo B, A/A, A/PI, 
Other 1 9% 0.31 0 0% 0.00 0% 
*†per 100000 population, estimates per US Census     
§ Total of Black, Am Indian/Alaskan Native, Asian/Pacific Islander, and Other   
 
TABLE 2-Cases & Deaths of IMD in MC by Race/Ethnicity in 2005  
   Cases   Deaths   
Race/Ethnicity   # % Rate* # % Rate† CFR 
White  12 63% 0.54 0 0% 0.00 0% 
Hispanic  6 32% 0.58 0 0% 0.00 0% 
Black  1 5% 0.72 1 100% 0.72 5% 
Am Indian/Alaskan Native 0 0% 0.00 0 0% 0.00 0% 
Asian/Pacific Islander 0 0% 0.00 0 0% 0.00 0% 
Other  0 0% 0.00 0 0% 0.00 0% 
Total  19 100% 0.52 1 100% 0.03 5% 
§Combo B, A/A, A/PI, 
Other 1 5% 0.29 1 100% 0.29 5% 
*†per 100000 population, estimates per US Census     
§ Total of Black, Am Indian/Alaskan Native, Asian/Pacific Islander, and Other   
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TABLE 2-Cases & Deaths of IMD in MC by Race/Ethnicity in 2006, 1/1-6/30 
   Cases   Deaths   
Race/Ethnicity   # % Rate # % Rate CFR 
White  2 40%   1 50%   20% 
Hispanic  2 40%   0 0%   0% 
Black  1 20%   1 50%   20% 
Am Indian/Alaskan Native 0 0%   0 0%   0% 
Asian/Pacific Islander 0 0%   0 0%   0% 
Other  0 0%   0 0%   0% 
Total  5 100%   2 100%   40% 
§Combo B, A/A, A/PI, 
Other 1 20%  1 50%  20% 
§ Total of Black, Am Indian/Alaskan Native, Asian/Pacific Islander, and Other   
 
TABLE 2-Cases & Deaths of IMD in MC by Race/Ethnicity    
 1/1/2000-6/30/2006      
   Cases    Deaths  
Race/Ethnicity   # % Rate # % Rate CFR 
White  58 51%  5 42%   4% 
Hispanic  44 39%  4 33%   4% 
Black  6 5%  2 17%   2% 
Am Indian/Alaskan Native 3 3%  1 8%   1% 
Asian/Pacific Islander 1 1%  0 0%   0% 
Other  1 1%  0 0%   0% 
Total  113 100%  12 100%   11% 
§Combo B, A/A, A/PI, 
Other 11 10%  3 25%   3% 
§ Total of Black, Am Indian/Alaskan Native, Asian/Pacific Islander, and Other   
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C. Cases & Deaths of Invasive Meningococcal Disease(IMD) in 
Maricopa County(MC) by Gender, 2000-2006, per year 
 
TABLE 3-Cases & Deaths of IMD in MC by Gender in 2000 
  Cases   Deaths  
Sex # % Rate* # % Rate† CFR 
Male 14 50% 0.90 0 0% 0.00 0% 
Female 14 50% 0.90 3 100% 0.19 11% 
Total 28 100% 0.90 3 100% 0.10 11% 
*†per 100000 population, estimates per US Census    
 
TABLE 3-Cases & Deaths of IMD in MC by Gender in 2001 
  Cases   Deaths  
Sex # % Rate* # % Rate† CFR 
Male 6 46% 0.37 0 0% 0.00 0% 
Female 7 54% 0.44 0 0% 0.00 0% 
Total 13 100% 0.41 0 0% 0.00 0% 
*†per 100000 population, estimates per US Census    
 
TABLE 3-Cases & Deaths of IMD in MC by Gender in 2002 
  Cases   Deaths  
Sex # % Rate* # % Rate† CFR 
Male 11 55% 0.67 2 40% 0.12 10% 
Female 9 45% 0.55 3 60% 0.18 15% 
Total 20 100% 0.61 5 100% 0.15 25% 
*†per 100000 population, estimates per US Census    
 
TABLE 3-Cases & Deaths of IMD in MC by Gender in 2003 
  Cases   Deaths  
Sex # % Rate* # % Rate† CFR 
Male 8 47% 0.47 0 0% 0.00 0% 
Female 9 53% 0.53 1 33% 0.06 6% 
Total 17 100% 0.50 1 100% 0.03 6% 
*†per 100000 population, estimates per US Census    
 
TABLE 3-Cases & Deaths of IMD in MC by Gender in 2004 
  Cases   Deaths  
Sex # % Rate* # % Rate† CFR 
Male 6 55% 0.34 0 0% 0.00 0% 
Female 5 45% 0.29 0 0% 0.00 0% 
Total 11 100% 0.31 0 0% 0.00 0% 
*†per 100000 population, estimates per US Census    
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TABLE 3-Cases & Deaths of IMD in MC by Gender in 2005 
  Cases   Deaths  
Sex # % Rate* # % Rate† CFR 
Male 10 53% 0.55 1 100% 0.05 5% 
Female 9 47% 0.50 0 0% 0.00 0% 
Total 19 100% 0.52 1 100% 0.03 5% 
*†per 100000 population, estimates per US Census    
 
TABLE 3-Cases & Deaths of IMD in MC by Gender in 2006, 1/1-6/30 
  Cases   Deaths   
Sex # % Rate  # %  Rate CFR  
Male 2 40%   1 50%   20%  
Female 3 60%   1 50%   20%  
Total 5 100%   2 100%   40%  
 
TABLE 3-Cases & Deaths of IMD in MC by Gender  
 1/1/2000-6/30/2006     
  Cases   Deaths  
Sex # % Rate # % Rate CFR 
Male 57 50%  4 33%  4% 
Female 56 50%  8 67%  7% 
Total 113 100%  12 100%  11% 
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D. Cases & Deaths of Invasive Meningococcal Disease(IMD) in 
Maricopa County(MC) by Age, 2000-2006, per year 
 
TABLE 4-Cases & Deaths of IMD in MC by Age in 2000  
  Cases   Deaths  
Age # % Rate* # % Rate† CFR 
<1 year 6 21%   0 0%   0% 
1 year 3 11%   0 0%   0% 
2-4 years 1 4%   1 33%   4% 
§0-4 years 10 36% 4.10 1 33% 0.41 4% 
5-9 years 1 4% 0.42 0 0% 0.00 0% 
10-13 years 3 11%   0 0%   0% 
14-17 years 2 7%   0 0%   0% 
18-24 years 2 7%   0 0%   0% 
§10-24years 7 25% 1.05 0 0% 0.00 0% 
25-64 years 5 18% 0.32 0 0% 0.00 0% 
65+ years 5 18% 1.38 2 67% 0.55 7% 
Total 28 100% 0.90 3 100% 0.10 11% 
*†per 100000 population, estimates per US Census    
     §Combined age groups for rate calculation purposes    
 
TABLE 4-Cases & Deaths of IMD in MC by Age in 2001  
  Cases   Deaths  
Age # % Rate* # % Rate† CFR 
<1 year 2 15%   0 0%   0% 
1 year 1 8%   0 0%   0% 
2-4 years 2 15%   0 0%   0% 
§0-4 years 5 38% 1.92 0 0% 0.00 0% 
5-9 years 1 8% 0.40 0 0% 0.00 0% 
10-13 years 0 0%   0 0%   0% 
14-17 years 1 8%   0 0%   0% 
18-24 years 0 0%   0 0%   0% 
§10-24years 1 8% 0.14 0 0% 0.00 0% 
25-64 years 4 31% 0.24 0 0% 0.00 0% 
65+ years 2 15% 0.54 0 0% 0.00 0% 
Total 13 100% 0.41 0 0% 0.00 0% 
*†per 100000 population, estimates per US Census    
     §Combined age groups for rate calculation purposes    
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TABLE 4-Cases & Deaths of IMD in MC by Age in 2002  
  Cases   Deaths  
Age # % Rate* # % Rate† CFR 
<1 year 5 25%   2 40%   10% 
1 year 0 0%   0 0%   0% 
2-4 years 2 10%   0 0%   0% 
§0-4 years 7 35% 2.59 2 40% 0.74 10% 
5-9 years 1 5% 0.39 0 0% 0.00 0% 
10-13 years 0 0%   0 0%   0% 
14-17 years 2 10%   1 20%   5% 
18-24 years 7 35%   2 40%   10% 
§10-24years 9 45% 1.27 3 60% 0.42 15% 
25-64 years 3 15% 0.18 0 0% 0.00 0% 
65+ years 0 0% 0.00 0 0% 0.00 0% 
Total 20 100% 0.61 5 100% 0.15 25% 
*†per 100000 population, estimates per US Census    
     §Combined age groups for rate calculation purposes    
 
TABLE 4-Cases & Deaths of IMD in MC by Age in 2003  
  Cases   Deaths  
Age # % Rate* # % Rate† CFR 
<1 year 5 29%   1 100%   6% 
1 year 0 0%   0 0%   0% 
2-4 years 3 18%   0 0%   0% 
§0-4 years 8 47% 2.85 1 100% 0.36 6% 
5-9 years 2 12% 0.76 0 0% 0.00 0% 
10-13 years 0 0%   0 0%   0% 
14-17 years 1 6%   0 0%   0% 
18-24 years 3 18%   0 0%   0% 
§10-24years 4 24% 0.55 0 0% 0.00 0% 
25-64 years 3 18% 0.17 0 0%   0% 
65+ years 0 0% 0.00 0 0% 0.00 0% 
Total 17 100% 0.50 1 100% 0.03 6% 
*†per 100000 population, estimates per US Census    
     §Combined age groups for rate calculation purposes    
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TABLE 4-Cases & Deaths of IMD in MC by Age in 2004  
  Cases   Deaths  
Age # % Rate* # % Rate† CFR 
<1 year 1 9%   0 0%   0% 
1 year 0 0%   0 0%   0% 
2-4 years 1 9%   0 0%   0% 
§0-4 years 2 18% 0.69 0 0% 0.00 0% 
5-9 years 1 9% 0.37 0 0% 0.00 0% 
10-13 years 2 18%   0 0%   0% 
14-17 years 1 9%   0 0%   0% 
18-24 years 0 0%   0 0%   0% 
§10-24years 3 27% 0.40 0 0% 0.00 0% 
25-64 years 3 27% 0.17 0 0% 0.00 0% 
65+ years 2 18% 0.51 0 0% 0.00 0% 
Total 11 100% 0.31 0 0% 0.00 0% 
*†per 100000 population, estimates per US Census    
     §Combined age groups for rate calculation purposes    
 
TABLE 4-Cases & Deaths of IMD in MC by Age in 2005  
  Cases   Deaths  
Age # % Rate* # % Rate† CFR 
<1 year 0 0%   0 0%   0% 
1 year 1 5%   0 0%   0% 
2-4 years 1 5%   1 100%   5% 
§0-4 years 2 11% 0.67 1 100% 0.33 5% 
5-9 years 1 5% 0.36 0 0% 0.00 0% 
10-13 years 0 0%   0 0%   0% 
14-17 years 3 16%   0 0%   0% 
18-24 years 3 16%   0 0%   0% 
§10-24years 6 32% 0.78 0 0% 0.00 0% 
25-64 years 8 42% 0.42 0 0% 0.00 0% 
65+ years 2 11% 0.50 0 0% 0.00 0% 
Total 19 100% 0.52 1 100% 0.03 5% 
*†per 100000 population, estimates per US Census    
     §Combined age groups for rate calculation purposes    
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TABLE 4-Cases & Deaths of IMD in MC by Age in 2006, 1/1-6/30 
  Cases   Deaths  
Age # % Rate # % Rate CFR 
<1 year 0 0%   0 0%   0% 
1 year 0 0%   0 0%   0% 
2-4 years 2 40%   0 0%   0% 
   §0-4 years 2 40%   0 0%   0% 
5-9 years 0 0%   0 0%   0% 
10-13 years 0 0%   0 0%   0% 
14-17 years 0 0%   0 0%   0% 
18-24 years 2 40%   1 50%   20% 
  §10-24 years 2 40%   1 50%   20% 
25-64 years 1 20%   1 50%   20% 
65+ years 0 0%   0 0%   0% 
Total 5 100%   2 100%   40% 
     §Combined age groups       
 
TABLE 4-Cases & Deaths of IMD in MC by Age    
 1/1/2000-6/30/2006     
 Cases     Deaths   
Age # % Rate # % Rate CFR 
<1 year 19 17%  3 25%   3% 
1 year 5 4%  0 0%   0% 
2-4 years 12 11%  2 17%   2% 
§0-4 years 36 32%  5 42%   4% 
5-9 years 7 6%  0 0%   0% 
10-13 years 5 4%  0 0%   0% 
14-17 years 10 9%  1 8%   1% 
18-24 years 17 15%  3 25%   3% 
§10-24years 32 28%  4 33%   4% 
25-64 years 27 24%  1 8%   1% 
65+ years 11 10%  2 17%   2% 
Total 113 100%  12 100%   11% 
     §Combined age groups       
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E. Cases & Deaths of Invasive Meningococcal Disease(IMD) in 
Maricopa County(MC) by Serogroup, 2000-2006, per year 
 
TABLE 5-Cases & Deaths of IMD in MC by Serogroup in 2000 
  Cases   Deaths   
Serogroup # % Rate* # % Rate† CFR 
Group B 5 18% 0.16 0 0% 0.00 0% 
Group C 1 4% 0.03 0 0% 0.00 0% 
Group Y 10 36% 0.32 2 67% 0.06 7% 
§Others 2 7% 0.06 1 33% 0.03 4% 
Not Groupable 7 25% 0.23 0 0% 0.00 0% 
Unknown 3 11% 0.10 0 0% 0.00 0% 
Total 28 100% 0.90 3 100% 0.10 11% 
*†per 100000 population, estimates per US Census    
     §Others=A & W-135 
 
 
TABLE 5-Cases & Deaths of IMD in MC by Serogroup in 2001 
  Cases   Deaths  
Serogroup # % Rate* # % Rate† CFR 
Group B 8 62% 0.25 0 0% 0.00 0% 
Group C 0 0% 0.00 0 0% 0.00 0% 
Group Y 3 23% 0.09 0 0% 0.00 0% 
§Others 0 0% 0.00 0 0% 0.00 0% 
Not Groupable 2 15% 0.06 0 0% 0.00 0% 
Unknown 0 0% 0.00 0 0% 0.00 0% 
Total 13 100% 0.41 0 0% 0.00 0% 
*†per 100000 population, estimates per US Census    
   §Others=A & W-135 
 
 
TABLE 5-Cases & Deaths of IMD in MC by Serogroup in 2002 
  Cases   Deaths  
Serogroup # % Rate* # % Rate† CFR 
Group B 10 50% 0.30 4 80% 0.12 20% 
Group C 6 30% 0.18 0 0% 0.00 0% 
Group Y 2 10% 0.06 0 0% 0.00 0% 
§Others 1 5% 0.03 0 0% 0.00 0% 
Not Groupable 0 0% 0.00 0 0% 0.00 0% 
Unknown 1 5% 0.03 1 20% 0.03 5% 
Total 20 100% 0.61 5 100% 0.15 25% 
*†per 100000 population, estimates per US Census    
    §Others=A & W-135 
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TABLE 5-Cases & Deaths of IMD in MC by Serogroup in 2003 
  Cases   Deaths  
Serogroup # % Rate* # % Rate† CFR 
Group B 2 12% 0.06 0 0% 0.00 0% 
Group C 5 29% 0.15 0 0% 0.00 0% 
Group Y 2 12% 0.06 0 0% 0.00 0% 
§Others 0 0% 0.00 0 0% 0.00 0% 
Not Groupable 6 35% 0.18 0 0% 0.00 0% 
Unknown 2 12% 0.06 1 100% 0.03 6% 
Total 17 100% 0.50 1 100% 0.03 6% 
*†per 100000 population, estimates per US Census    
   §Others=A & W-135 
 
TABLE 5-Cases & Deaths of IMD in MC by Serogroup in 2004 
  Cases   Deaths  
Serogroup # % Rate* # % Rate† CFR 
Group B 0 0% 0.00 0 0% 0.00 0% 
Group C 2 18% 0.06 0 0% 0.00 0% 
Group Y 3 27% 0.09 0 0% 0.00 0% 
§Others 0 0% 0.00 0 0% 0.00 0% 
Not Groupable 1 9% 0.03 0 0% 0.00 0% 
Unknown 5 45% 0.14 0 0% 0.00 0% 
Total 11 100% 0.31 0 0% 0.00 0% 
*†per 100000 population, estimates per US Census    
   §Others=A & W-135 
 
TABLE 5-Cases & Deaths of IMD in MC by Serogroup in 2005 
  Cases   Deaths   
Serogroup # % Rate* # % Rate† CFR 
Group B 4 21% 0.11 1 100% 0.03 5% 
Group C 5 26% 0.14 0 0% 0.00 0% 
Group Y 2 11% 0.06 0 0% 0.00 0% 
§Others 1 5% 0.03 0 0% 0.00 0% 
Not Groupable 2 11% 0.06 0 0% 0.00 0% 
Unknown 5 26% 0.14 0 0% 0.00 0% 
Total 19 100% 0.52 1 100% 0.03 5% 
*†per 100000 population, estimates per US Census    
   §Others=A & W-135 
TABLE 5-Cases & Deaths of IMD in MC by Serogroup in 2006,1/1-6/30 
  Cases   Deaths  
Serogroup # % Rate # % Rate CFR 
Group B 0 0%   0 0%   0% 
Group C 0 0%   0 0%   0% 
Group Y 2 40%   1 33%   20% 
§Others 0 0%   0 0%   0% 
Not Groupable 0 0%   0 0%   0% 
Unknown 3 60%   1 33%   20% 
Total 5 100%   2 100%   40% 
   §Others=A & W-135 
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TABLE 5-Cases & Deaths of IMD in MC by Serogroup   
 2000-2005      
  Cases   Deaths  
Serogroup # % Rate # % Rate CFR 
Group B 29 27% 0.14 5 42%   5% 
Group C 19 18% 0.09 0 0%   0% 
Group Y 22 20% 0.11 2 17%   2% 
§Others 4 4% 0.02 1 8%   1% 
Not Groupable 18 17% 0.09 0 0%   0% 
Unknown 16 15% 0.08 2 17%   2% 
Total 108 100% 0.54 10 83%   9% 
*†per 100000 population, estimates per US Census    
   §Others=A & W-135 
 
TABLE 5-Cases & Death of IMD in MC by Serogroup    
 1/1/2000-6/302006     
  Cases   Deaths   
Serogroup # % Rate # % Rate CFR 
Group B 29 26%   5 42%   4% 
Group C 19 17%   0 0%   0% 
Group Y 24 21%   3 25%   3% 
§Others 4 4%   1 8%   1% 
Not Groupable 18 16%   0 0%   0% 
Unknown 19 17%   3 25%   3% 
Total 113 100%   12 100%   11% 
    §Others=A & W-135 
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F. Invasive Meningococcal Disease(IMD) in Maricopa County(MC) by 
Serogroup and Age, 2000-2006, per year 
 
TABLE 9- IMD in MC by Serogroup and Age-2000    
   Serogroup    
     Not   
Age 
Group 
B 
Group 
C 
Group 
Y §Others Groupable Unknown Total 
<1 year                      # 1 0 0 0 3 2 6 
 Serogroup by age    % 17% 0% 0% 0% 50% 33% 100% 
 Age by serogroup    % 20% 0% 0% 0% 43% 67% 21% 
1 year                        # 0 0 2 1 0 0 3 
 Serogroup by age    % 0% 0% 67% 33% 0% 0% 100% 
 Age by serogroup    % 0% 0% 20% 50% 0% 0% 11% 
2-4 years                  # 0 0 0 1 0 0 1 
 Serogroup by age    % 0% 0% 0% 100% 0% 0% 100% 
 Age by serogroup    % 0% 0% 0% 50% 0% 0% 4% 
5-9 years                  # 0 1 0 0 0 0 1 
 Serogroup by age    % 0% 100% 0% 0% 0% 0% 100% 
 Age by serogroup    % 0% 100% 0% 0% 0% 0% 4% 
10-13 years              # 1 0 1 0 1 0 3 
 Serogroup by age    % 33% 0% 33% 0% 33% 0% 100% 
 Age by serogroup    % 20% 0% 10% 0% 14% 0% 11% 
14-17 years              #            1 0 1 0 0 0 2 
 Serogroup by age    % 50% 0% 50% 0% 0% 0% 100% 
 Age by serogroup    % 20% 0% 10% 0% 0% 0% 7% 
18-24 years              # 1 0 0 0 1 0 2 
 Serogroup by age    % 50% 0% 0% 0% 50% 0% 100% 
 Age by serogroup    % 20% 0% 0% 0% 14% 0% 7% 
25-64 years             # 1 0 2 0 1 1 5 
 Serogroup by age    % 20% 0% 40% 0% 20% 20% 100% 
 Age by serogroup    % 20% 0% 20% 0% 14% 33% 18% 
65+ years                 # 0 0 4 0 1 0 5 
 Serogroup by age    % 0% 0% 80% 0% 20% 0% 100% 
 Age by serogroup    % 0% 0% 40% 0% 14% 0% 18% 
Total                          # 5 1 10 2 7 3 28 
                                      % 18% 4% 36% 7% 25% 11% 100% 
 Age by serogroup    % 100% 100% 100% 100% 100% 100%   
§Others=A & W-135 
  
 
 
 
 
 
 42
 
 
TABLE 9- IMD in MC by Serogroup and Age-2001    
   Serogroup    
     Not   
Age 
Group 
B 
Group 
C 
Group 
Y §Others Groupable Unknown Total 
<1 year                      # 1 0 1 0 0 0 2 
 Serogroup by age    % 50% 0% 50% 0% 0% 0% 100% 
 Age by serogroup    % 13% 0% 33% 0% 0% 0% 15% 
1 year                        # 0 0 0 0 1 0 1 
 Serogroup by age    % 0% 0% 0% 0% 100% 0% 100% 
 Age by serogroup    % 0% 0% 0% 0% 50% 0% 8% 
2-4 years                  # 2 0 0 0 0 0 2 
 Serogroup by age    % 100% 0% 0% 0% 0% 0% 100% 
 Age by serogroup    % 25% 0% 0% 0% 0% 0% 15% 
5-9 years                  # 1 0 0 0 0 0 1 
 Serogroup by age    % 100% 0% 0% 0% 0% 0% 100% 
 Age by serogroup    % 13% 0% 0% 0% 0% 0% 8% 
10-13 years              # 0 0 0 0 0 0 0 
 Serogroup by age    % 0% 0% 0% 0% 0% 0% 0% 
 Age by serogroup    % 0% 0% 0% 0% 0% 0% 0% 
14-17 years              #            0 0 1 0 0 0 1 
 Serogroup by age    % 0% 0% 100% 0% 0% 0% 100% 
 Age by serogroup    % 0% 0% 33% 0% 0% 0% 8% 
18-24 years              # 0 0 0 0 0 0 0 
 Serogroup by age    % 0% 0% 0% 0% 0% 0% 0% 
 Age by serogroup    % 0% 0% 0% 0% 0% 0% 0% 
25-64 years             # 3 0 0 0 1 0 4 
 Serogroup by age    % 75% 0% 0% 0% 25% 0% 100% 
 Age by serogroup    % 38% 0% 0% 0% 50% 0% 31% 
65+ years                 # 1 0 1 0 0 0 2 
 Serogroup by age    % 50% 0% 50% 0% 0% 0% 100% 
 Age by serogroup    % 13% 0% 33% 0% 0% 0% 15% 
Total                          # 8 0 3 0 2 0 13 
 Serogroup by age    % 62% 0% 23% 0% 15% 0% 100% 
 Age by serogroup    % 100% 0% 100% 0% 100% 0%   
§Others=A & W-135 
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TABLE 9- IMD in MC by Serogroup and Age-2002    
   Serogroup    
     Not   
Age 
Group 
B 
Group 
C 
Group 
Y §Others Groupable Unknown Total 
<1 year                      # 4 0 1 0 0 0 5 
 Serogroup by age    % 80% 0% 20% 0% 0% 0% 100% 
 Age by serogroup    % 40% 0% 50% 0% 0% 0% 25% 
1 year                        # 0 0 0 0 0 0 0 
 Serogroup by age    % 0% 0% 0% 0% 0% 0% 0% 
 Age by serogroup    % 0% 0% 0% 0% 0% 0% 0% 
2-4 years                  # 1 0 0 1 0 0 2 
 Serogroup by age    % 50% 0% 0% 50% 0% 0% 100% 
 Age by serogroup    % 10% 0% 0% 100% 0% 0% 10% 
5-9 years                  # 0 1 0 0 0 0 1 
 Serogroup by age    % 0% 100% 0% 0% 0% 0% 0% 
 Age by serogroup    % 0% 14% 0% 0% 0% 0% 5% 
10-13 years              # 0 0 0 0 0 0 0 
 Serogroup by age    % 0% 0% 0% 0% 0% 0% 0% 
 Age by serogroup    % 0% 0% 0% 0% 0% 0% 0% 
14-17 years              #            0 0 1 0 0 1 2 
 Serogroup by age    % 0% 0% 50% 0% 0% 50% 100% 
 Age by serogroup    % 0% 0% 50% 0% 0% 100% 10% 
18-24 years              # 5 2 0 0 0 0 7 
 Serogroup by age    % 71% 29% 0% 0% 0% 0% 100% 
 Age by serogroup    % 50% 29% 0% 0% 0% 0% 35% 
25-64 years             # 0 3 0 0 0 0 3 
 Serogroup by age    % 0% 100% 0% 0% 0% 0% 100% 
 Age by serogroup    % 0% 43% 0% 0% 0% 0% 15% 
65+ years                 # 0 0 0 0 0 0 0 
 Serogroup by age    % 0% 0% 0% 0% 0% 0% 0% 
 Age by serogroup    % 0% 0% 0% 0% 0% 0% 0% 
Total                          # 10 6 2 1 0 1 20 
 Serogroup by age    % 50% 30% 10% 5% 0% 5% 100% 
 Age by serogroup    % 100% 86% 100% 100% 0% 100%   
§Others=A & W-135 
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TABLE 9- IMD in MC by Serogroup and Age-2003    
   Serogroup    
     Not   
Age 
Group 
B 
Group 
C 
Group 
Y §Others Groupable Unknown Total 
<1 year                      # 0 0 0 0 4 1 5 
 Serogroup by age    % 0% 0% 0% 0% 80% 20% 100% 
 Age by serogroup    % 0% 0% 0% 0% 67% 50% 29% 
1 year                        # 0 0 0 0 0 0 0 
 Serogroup by age    % 0% 0% 0% 0% 0% 0% 0% 
 Age by serogroup    % 0% 0% 0% 0% 0% 0% 0% 
2-4 years                  # 1 0 0 0 1 1 3 
 Serogroup by age    % 33% 0% 0% 0% 33% 33% 100% 
 Age by serogroup    % 50% 0% 0% 0% 17% 50% 18% 
5-9 years                  # 0 1 0 0 1 0 2 
 Serogroup by age    % 0% 50% 0% 0% 50% 0% 100% 
 Age by serogroup    % 0% 20% 0% 0% 17% 0% 12% 
10-13 years              # 0 0 0 0 0 0 0 
 Serogroup by age    % 0% 0% 0% 0% 0% 0% 1% 
 Age by serogroup    % 0% 0% 0% 0% 0% 0% 0% 
14-17 years              #            0 1 0 0 0 0 1 
 Serogroup by age    % 0% 100% 0% 0% 0% 0% 100% 
 Age by serogroup    % 0% 20% 0% 0% 0% 0% 6% 
18-24 years              # 0 2 1 0 0 0 3 
 Serogroup by age    % 0% 67% 33% 0% 0% 0% 100% 
 Age by serogroup    % 0% 40% 50% 0% 0% 0% 18% 
25-64 years             # 1 1 1 0 0 0 3 
 Serogroup by age    % 33% 33% 33% 0% 0% 0% 100% 
 Age by serogroup    % 50% 20% 50% 0% 0% 0% 18% 
65+ years                 # 0 0 0 0 0 0 0 
 Serogroup by age    % 0% 0% 0% 0% 0% 0% 0% 
 Age by serogroup    % 0% 0% 0% 0% 0% 0% 0% 
Total                          # 2 5 2 0 6 2 17 
 Serogroup by age    % 0% 0% 12% 0% 35% 12% 100% 
 Age by serogroup    % 100% 100% 100% 0% 100% 100%   
§Others=A & W-135 
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TABLE 9- IMD in MC by Serogroup and Age-2004    
   Serogroup    
     Not   
Age 
Group 
B 
Group 
C 
Group 
Y §Others Groupable Unknown Total 
<1 year                      # 0 0 1 0 0 0 1 
 Serogroup by age    % 0% 0% 100% 0% 0% 0% 100% 
 Age by serogroup    % 0% 0% 33% 0% 0% 0% 9% 
1 year                        # 0 0 0 0 0 0 0 
 Serogroup by age    % 0% 0% 0% 0% 0% 0% 0% 
 Age by serogroup    % 0% 0% 0% 0% 0% 0% 0% 
2-4 years                  # 0 0 0 0 0 1 1 
 Serogroup by age    % 0% 0% 0% 0% 0% 100% 100% 
 Age by serogroup    % 0% 0% 0% 0% 0% 20% 9% 
5-9 years                  # 0 0 0 0 0 1 1 
 Serogroup by age    % 0% 0% 0% 0% 0% 100% 100% 
 Age by serogroup    % 0% 0% 0% 0% 0% 20% 9% 
10-13 years              # 0 1 0 0 1 0 2 
 Serogroup by age    % 0% 50% 0% 0% 50% 0% 100% 
 Age by serogroup    % 0% 50% 0% 0% 100% 0% 18% 
14-17 years              #            0 0 0 0 0 1 1 
 Serogroup by age    % 0% 0% 0% 0% 0% 100% 100% 
 Age by serogroup    % 0% 0% 0% 0% 0% 20% 9% 
18-24 years              # 0 0 0 0 0 0 0 
 Serogroup by age    % 0% 0% 0% 0% 0% 0% 0% 
 Age by serogroup    % 0% 0% 0% 0% 0% 0% 0% 
25-64 years             # 0 1 1 0 0 1 3 
 Serogroup by age    % 0% 33% 33% 0% 0% 33% 100% 
 Age by serogroup    % 0% 50% 33% 0% 0% 20% 27% 
65+ years                 # 0 0 1 0 0 1 2 
 Serogroup by age    % 0% 0% 50% 0% 0% 50% 100% 
 Age by serogroup    % 0% 0% 33% 0% 0% 20% 18% 
Total                          # 0 2 3 0 1 5 11 
 Serogroup by age    % 0% 18% 27% 0% 9% 45% 100% 
 Age by serogroup    % 0% 100% 100% 0% 100% 100%   
§Others=A & W-135 
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TABLE 9- IMD in MC by Serogroup and Age-2005    
   Serogroup    
     Not   
Age 
Group 
B 
Group 
C 
Group 
Y §Others Groupable Unknown Total 
<1 year                      # 0 0 0 0 0 0 0 
 Serogroup by age    % 0% 0% 0% 0% 0% 0% 0% 
 Age by serogroup    % 0% 0% 0% 0% 0% 0% 0% 
1 year                        # 0 0 0 0 0 1 1 
 Serogroup by age    % 0% 0% 0% 0% 0% 100% 100% 
 Age by serogroup    % 0% 0% 0% 0% 0% 50% 5% 
2-4 years                  # 1 0 0 0 0 0 1 
 Serogroup by age    % 100% 0% 0% 0% 0% 0% 100% 
 Age by serogroup    % 25% 0% 0% 0% 0% 0% 5% 
5-9 years                  # 0 0 0 0 0 1 1 
 Serogroup by age    % 0% 0% 0% 0% 0% 100% 100% 
 Age by serogroup    % 0% 0% 0% 0% 0% 20% 5% 
10-13 years              # 0 0 0 0 0 0 0 
 Serogroup by age    % 0% 0% 0% 0% 0% 0% 0% 
 Age by serogroup    % 0% 0% 0% 0% 0% 0% 0% 
14-17 years              #            1 1 0 0 0 1 3 
 Serogroup by age    % 33% 33% 0% 0% 0% 33% 0% 
 Age by serogroup    % 25% 20% 0% 0% 0% 20% 16% 
18-24 years              # 1 1 0 0 0 1 3 
 Serogroup by age    % 33% 33% 0% 0% 0% 33% 100% 
 Age by serogroup    % 25% 20% 0% 0% 0% 20% 16% 
25-64 years             # 1 3 2 0 1 1 8 
 Serogroup by age    % 13% 38% 25% 0% 13% 13% 100% 
 Age by serogroup    % 25% 60% 100% 0% 50% 20% 42% 
65+ years                 # 0 0 0 1 1   2 
 Serogroup by age    % 0% 0% 0% 50% 50% 0% 100% 
 Age by serogroup    % 0% 0% 0% 100% 50% 0% 11% 
Total                          # 4 5 2 1 2 5 19 
 Serogroup by age    % 21% 26% 11% 5% 11% 26% 100% 
 Age by serogroup    % 100% 100% 100% 100% 100% 100%   
§Others=A & W-135 
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TABLE 9- IMD in MC by Serogroup and Age-2006, 1/1-6/30    
   Serogroup    
     Not   
Age 
Group 
B 
Group 
C 
Group 
Y §Others Groupable Unknown Total 
<1 year                      # 0 0 0 0 0 0 0 
 Serogroup by age    % 0% 0% 0% 0% 0% 0% 0% 
 Age by serogroup    % 0% 0% 0% 0% 0% 0% 0% 
1 year                        # 0 0 0 0 0 0 0 
 Serogroup by age    % 0% 0% 0% 0% 0% 0% 0% 
 Age by serogroup    % 0% 0% 0% 0% 0% 0% 0% 
2-4 years                  #  0 1 0 0 1 2 
 Serogroup by age    % 0% 0% 50% 0% 0% 50% 100% 
 Age by serogroup    % 0% 0% 50% 0% 0% 33% 40% 
5-9 years                  # 0 0 0 0 0 0 0 
 Serogroup by age    % 0% 0% 0% 0% 0% 0% 0% 
 Age by serogroup    % 0% 0% 0% 0% 0% 0% 0% 
10-13 years              # 0 0 0 0 0 0 0 
 Serogroup by age    % 0% 0% 0% 0% 0% 0% 0% 
 Age by serogroup    % 0% 0% 0% 0% 0% 0% 0% 
14-17 years              #            0 0 0 0 0 0 0 
 Serogroup by age    % 0% 0% 0% 0% 0% 0% 0% 
 Age by serogroup    % 0% 0% 0% 0% 0% 0% 0% 
18-24 years              # 0 0 0 0 0 2 2 
 Serogroup by age    % 0% 0% 0% 0% 0% 100% 100% 
 Age by serogroup    % 0% 0% 0% 0% 0% 67% 40% 
25-64 years             # 0 0 1 0 0 0 1 
 Serogroup by age    % 0% 0% 100% 0% 0% 0% 100% 
 Age by serogroup    % 0% 0% 50% 0% 0% 0% 20% 
65+ years                 # 0 0 0 0 0 0 0 
 Serogroup by age    % 0% 0% 0% 0% 0% 0% 0% 
 Age by serogroup    % 0% 0% 0% 0% 0% 0% 0% 
Total                          # 0 0 2 0 0 3 5 
     % 0% 0% 40% 0% 0% 60% 100% 
 Age by serogroup    % 0% 0% 100% 0% 0% 100%   
§Others=A & W-135 
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TABLE 9-IMD in MC by Serogroup and Age 2000-2005     
       
   Serogroup    
     Not   
Age 
Group 
B 
Group 
C 
Group 
Y §Others Groupable Unknown Total 
<1 year                      # 6 0 3 0 7 3 19 
 Serogroup by age    % 32% 0% 16% 0% 37% 16% 100% 
 Age by serogroup    % 21% 0% 14% 0% 39% 19% 18% 
1 year                        # 0 0 2 1 1 1 5 
 Serogroup by age    % 0% 0% 40% 20% 20% 20% 100% 
 Age by serogroup    % 0% 0% 9% 25% 6% 6% 5% 
2-4 years                  # 5 0 0 2 1 2 10 
 Serogroup by age    % 50% 0% 0% 20% 10% 20% 100% 
 Age by serogroup    % 17% 0% 0% 50% 6% 13% 9% 
5-9 years                  # 1 3 0 0 1 2 7 
 Serogroup by age    % 14% 43% 0% 0% 14% 29% 100% 
 Age by serogroup    % 3% 16% 0% 0% 6% 13% 6% 
10-13 years              # 1 1 1 0 2 0 5 
 Serogroup by age    % 20% 20% 20% 0% 40% 0% 100% 
 Age by serogroup    % 3% 5% 5% 0% 11% 0% 5% 
14-17 years              #            2 2 3 0 0 3 10 
 Serogroup by age    % 20% 20% 30% 0% 0% 30% 100% 
 Age by serogroup    % 7% 11% 14% 0% 0% 19% 9% 
18-24 years              # 7 5 1 0 1 1 15 
 Serogroup by age    % 47% 33% 7% 0% 7% 7% 100% 
 Age by serogroup    % 24% 26% 5% 0% 6% 6% 14% 
25-64 years             # 6 8 6 0 3 3 26 
 Serogroup by age    % 23% 31% 23% 0% 12% 12% 100% 
 Age by serogroup    % 21% 42% 27% 0% 17% 19% 24% 
65+ years                 # 1 0 6 1 2 1 11 
 Serogroup by age    % 8% 0% 50% 8% 17% 8% 92% 
 Age by serogroup    % 3% 0% 27% 25% 11% 6% 10% 
Total                          # 29 19 22 4 18 16 108 
                                      % 27% 18% 20% 4% 17% 15% 100% 
 Age by serogroup    % 100% 100% 100% 100% 100% 100%   
§Others=A & W-135 
 
 
 
 
 
 
 
 
 49
 
TABLE 9- IMD in MC by Serogroup and Age     
  1/1/2000-6/30/2006    
   Serogroup    
     Not   
Age 
Group 
B 
Group 
C 
Group 
Y §Others Groupable Unknown Total 
<1 year                      # 6 0 3 0 7 3 19 
 Serogroup by age    % 32% 0% 16% 0% 37% 16% 100% 
 Age by serogroup    % 21% 0% 13% 0% 39% 16% 17% 
1 year                        # 0 0 2 1 1 1 5 
 Serogroup by age    % 0% 0% 40% 20% 20% 20% 100% 
 Age by serogroup    % 0% 0% 8% 25% 6% 5% 4% 
2-4 years                  # 5 0 1 2 1 3 12 
 Serogroup by age    % 42% 0% 8% 17% 8% 25% 100% 
 Age by serogroup    % 17% 0% 4% 50% 6% 16% 11% 
5-9 years                  # 1 3 0 0 1 2 7 
 Serogroup by age    % 14% 43% 0% 0% 14% 29% 100% 
 Age by serogroup    % 3% 16% 0% 0% 6% 11% 6% 
10-13 years              # 1 1 1 0 2 0 5 
 Serogroup by age    % 20% 20% 20% 0% 40% 0% 100% 
 Age by serogroup    % 3% 5% 4% 0% 11% 0% 4% 
14-17 years              #            2 2 3 0 0 3 10 
 Serogroup by age    % 20% 20% 30% 0% 0% 30% 100% 
 Age by serogroup    % 7% 11% 13% 0% 0% 16% 9% 
18-24 years              # 7 5 1 0 1 3 17 
 Serogroup by age    % 41% 29% 6% 0% 6% 18% 100% 
 Age by serogroup    % 24% 26% 4% 0% 6% 16% 15% 
25-64 years             # 6 8 7 0 3 3 27 
 Serogroup by age    % 22% 30% 26% 0% 11% 11% 100% 
 Age by serogroup    % 21% 42% 29% 0% 17% 16% 24% 
65+ years                 # 1 0 6 1 2 1 11 
 Serogroup by age    % 8% 0% 50% 8% 17% 8% 92% 
 Age by serogroup    % 3% 0% 25% 25% 11% 5% 10% 
Total                          # 29 19 24 4 18 19 113 
                                      % 26% 17% 21% 4% 16% 17% 100% 
 Age by serogroup    % 100% 100% 100% 100% 100% 100%   
§Others=A & W-135 
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G. Invasive Meningococcal Disease(IMD) in Maricopa County(MC) by 
Serogroup and Race/Ethnicity, 2000-2006, per year 
 
TABLE 7- IMD in MC by Serogroup and Race/Ethnicity-2000   
   Serogroup     
     Not   
Race/Ethnicity 
Group 
B 
Group 
C Group Y §Others Groupable Unknown Total 
White                        #   2 1 5 0 4 0 12 
 Serogroup by race   % 17% 8% 42% 0% 33% 0% 100% 
 Race by serogroup % 40% 100% 50% 0% 57% 0% 43% 
Hispanic                 # 1 0 3 2 3 1 10 
 Serogroup by race   % 10% 0% 30% 20% 30% 10% 100% 
 Race by serogroup % 20% 0% 30% 100% 43% 33% 36% 
Black                      # 0 0 2 0 0 1 3 
 Serogroup by race   % 0% 0% 67% 0% 0% 33% 100% 
 Race by serogroup % 0% 0% 20% 0% 0% 33% 11% 
Am Indian/Al Native # 2 0 0 0 0 0 2 
 Serogroup by race   % 100% 0% 0% 0% 0% 11% 100% 
 Race by serogroup % 40% 0% 0% 0% 0% 0% 7% 
Asian/Pacific Islander# 0 0 0 0 0 1 1 
 Serogroup by race   % 0% 0% 0% 0% 0% 100% 100% 
 Race by serogroup % 0% 0% 0% 0% 0% 33% 4% 
Unknown                # 0 0 0 0 0 0 0 
 Serogroup by race   % 0% 0% 0% 0% 0% 0% 100% 
 Race by serogroup % 0% 0% 0% 0% 0% 0% 0% 
Total                       # 5 1 10 2 7 3 28 
                                       %  18% 4% 36% 7% 25% 11% 100% 
 Race by serogroup % 100% 100% 100% 100% 100% 100%   
§Others=A & W-135 
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TABLE 7- IMD in MC by Serogroup and Race/Ethnicity-2001   
   Serogroup     
     Not   
Race/Ethnicity 
Group 
B 
Group 
C Group Y §Others Groupable Unknown Total 
White                               #   3 2 0 0 1 0 6 
 Serogroup by race   % 50% 33% 0% 0% 17% 0% 100% 
 Race by serogroup % 38% 67% 0% 0% 50% 0% 46% 
Hispanic                         # 5 1 0 0 1 0 7 
 Serogroup by race   % 71% 14% 0% 0% 14% 0% 100% 
 Race by serogroup % 63% 33% 0% 0% 50% 0% 54% 
Black                               # 0 0 0 0 0 0 0 
 Serogroup by race   % 0% 0% 0% 0% 0% 0% 0% 
 Race by serogroup % 0% 0% 0% 0% 0% 0% 0% 
Am Indian/Al Native    # 0 0 0 0 0 0 0 
 Serogroup by race   % 0% 0% 0% 0% 0% 0% 0% 
 Race by serogroup % 0% 0% 0% 0% 0% 0% 0% 
Asian/Pacific Islander# 0 0 0 0 0 0 0 
 Serogroup by race   % 0% 0% 0% 0% 0% 0% 0% 
 Race by serogroup % 0% 0% 0% 0% 0% 0% 0% 
Unknown                        # 0 0 0 0 0 0 0 
 Serogroup by race   % 0% 0% 0% 0% 0% 0% 0% 
 Race by serogroup % 0% 0% 0% 0% 0% 0% 0% 
Total                               # 8 3 0 0 2 0 13 
                                       %  62% 23% 0% 0% 15% 0% 100% 
 Race by serogroup % 100% 100% 0% 0% 100% 0%   
§Others=A & W-135 
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TABLE 7- IMD in MC by Serogroup and Race/Ethnicity-2002   
   Serogroup     
     Not   
Race/Ethnicity 
Group 
B 
Group 
C Group Y §Others Groupable Unknown Total 
White                               #   5 4 0 0 0 1 10 
 Serogroup by race   % 50% 40% 0% 0% 0% 10% 100% 
 Race by serogroup % 50% 67% 0% 0% 0% 100% 50% 
Hispanic                         # 5 2 2 1 0 0 10 
 Serogroup by race   % 50% 20% 20% 10% 0% 0% 100% 
 Race by serogroup % 50% 33% 100% 100% 0% 0% 50% 
Black                               # 0 0 0 0 0 0 0 
 Serogroup by race   % 0% 0% 0% 0% 0% 0% 0% 
 Race by serogroup % 0% 0% 0% 0% 0% 0% 0% 
Am Indian/Al Native    # 0 0 0 0 0 0 0 
 Serogroup by race   % 0% 0% 0% 0% 0% 0% 0% 
 Race by serogroup % 0% 0% 0% 0% 0% 0% 0% 
Asian/Pacific Islander# 0 0 0 0 0 0 0 
 Serogroup by race   % 0% 0% 0% 0% 0% 0% 0% 
 Race by serogroup % 0% 0% 0% 0% 0% 0% 0% 
Unknown                        # 0 0 0 0 0 0 0 
 Serogroup by race   % 0% 0% 0% 0% 0% 0% 0% 
 Race by serogroup % 0% 0% 0% 0% 0% 0% 0% 
Total                               # 10 6 2 1 0 1 20 
                                       %  36% 21% 7% 4% 0% 4% 100% 
 Race by serogroup % 100% 100% 100% 100% 0% 100%   
§Others=A & W-135 
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TABLE 7- IMD in MC by Serogroup and Race/Ethnicity-2003   
   Serogroup     
     Not   
Race/Ethnicity 
Group 
B 
Group 
C Group Y §Others Groupable Unknown Total 
White                               #   0 4 1 0 3 0 8 
 Serogroup by race   % 0% 50% 13% 0% 38% 0% 100% 
 Race by serogroup % 0% 80% 50% 0% 50% 0% 47% 
Hispanic                         # 1 1 1 0 3 1 7 
 Serogroup by race   % 14% 14% 14% 0% 43% 14% 100% 
 Race by serogroup % 50% 20% 50% 0% 50% 50% 41% 
Black                               # 0 0 0 0 0 0 0 
 Serogroup by race   % 0% 0% 0% 0% 0% 0% 0% 
 Race by serogroup % 0% 0% 0% 0% 0% 0% 0% 
Am Indian/Al Native    # 0 0 0 0 0 1 1 
 Serogroup by race   % 0% 0% 0% 0% 0% 100% 100% 
 Race by serogroup % 0% 0% 0% 0% 0% 50% 6% 
Asian/Pacific Islander# 0 0 0 0 0 0 0 
 Serogroup by race   % 0% 0% 0% 0% 0% 0% 0% 
 Race by serogroup % 0% 0% 0% 0% 0% 0% 0% 
Unknown                        # 1 0 0 0 0 0% 1 
 Serogroup by race   % 0% 0% 0% 0% 0% 0% 0% 
 Race by serogroup % 50% 0% 0% 0% 0% 0% 6% 
Total                               # 2 5 2 0 6 2 17 
                                       %  12% 29% 12% 0% 35% 12% 100% 
 Race by serogroup % 40% 100% 100% 0% 100% 100%   
§Others=A & W-135 
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TABLE 7- IMD in MC by Serogroup and Race/Ethnicity-2004   
   Serogroup     
     Not   
Race/Ethnicity 
Group 
B 
Group 
C Group Y §Others Groupable Unknown Total 
White                               #   0 1 3 0 0 4 8 
 Serogroup by race   % 0% 13% 38% 0% 0% 50% 100% 
 Race by serogroup % 0% 50% 100% 0% 0% 80% 73% 
Hispanic                         # 0 0 0 0 1 1 2 
 Serogroup by race   % 0% 0% 0% 0% 50% 50% 100% 
 Race by serogroup % 0% 0% 0% 0% 100% 20% 18% 
Black                               # 0 1 0 0 0 0 1 
 Serogroup by race   % 0% 100% 0% 0% 0% 0% 100% 
 Race by serogroup % 0% 50% 0% 0% 0% 0% 9% 
Am Indian/Al Native    # 0 0 0 0 0 0 0 
 Serogroup by race   % 0% 25% 0% 0% 0% 0% 0% 
 Race by serogroup % 0% 0% 0% 0% 0% 0% 0% 
Asian/Pacific Islander# 0 0 0 0 0 0 0 
 Serogroup by race   % 0% 0% 0% 0% 0% 0% 0% 
 Race by serogroup % 0% 0% 0% 0% 0% 0% 0% 
Unknown                        # 0 0 0 0 0 0 0 
 Serogroup by race   % 0% 0% 0% 0% 0% 0% 0% 
 Race by serogroup % 0% 0% 0% 0% 0% 0% 0% 
Total                               # 0 2 3 0 1 5 11 
                                       %  0% 7% 11% 0% 4% 18% 100% 
 Race by serogroup % 0% 100% 100% 0% 100% 100%   
§Others=A & W-135 
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TABLE 7- IMD in MC by Serogroup and Race/Ethnicity-2005   
   Serogroup     
     Not   
Race/Ethnicity 
Group 
B 
Group 
C Group Y §Others Groupable Unknown Total 
White                               #   1 2 1 1 2 5 12 
 Serogroup by race   % 8% 17% 8% 8% 17% 42% 100% 
 Race by serogroup % 25% 40% 50% 100% 100% 100% 63% 
Hispanic                         # 2 3 1 0 0 0 6 
 Serogroup by race   % 33% 50% 17% 0% 0% 0% 100% 
 Race by serogroup % 50% 60% 50% 0% 0% 0% 32% 
Black                               # 1 0 0 0 0 0 1 
 Serogroup by race   % 100% 0% 0% 0% 0% 0% 100% 
 Race by serogroup % 25% 0% 0% 0% 0% 0% 5% 
Am Indian/Al Native    # 0 0 0 0 0 0 0 
 Serogroup by race   % 0% 0% 0% 0% 0% 0% 0% 
 Race by serogroup % 0% 0% 0% 0% 0% 0% 0% 
Asian/Pacific Islander# 0 0 0 0 0 0 0 
 Serogroup by race   % 0% 0% 0% 0% 0% 0% 0% 
 Race by serogroup % 0% 0% 0% 0% 0% 0% 0% 
Unknown                        # 0 0 0 0 0 0 0 
 Serogroup by race   % 0% 0% 0% 0% 0% 0% 0% 
 Race by serogroup % 0% 0% 0% 0% 0% 0% 0% 
Total                               # 4 5 2 1 2 5 19 
                                       %  14% 18% 7% 4% 7% 18% 100% 
 Race by serogroup % 100% 100% 100% 100% 100% 100%   
§Others=A & W-135 
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TABLE 7- IMD in MC by Serogroup and Race/Ethnicity-2006, 1/1-6/30   
   Serogroup     
     Not   
Race/Ethnicity 
Group 
B 
Group 
C Group Y §Others Groupable Unknown Total 
White                               #   0 0 1 0 0 1 2 
 Serogroup by race   % 0% 0% 50% 0% 0% 50% 100% 
 Race by serogroup % 0% 0% 50% 0% 0% 33% 40% 
Hispanic                         # 0 0 1 0 0 1 2 
 Serogroup by race   % 0% 0% 50% 0% 0% 50% 100% 
 Race by serogroup % 0% 0% 50% 0% 0% 33% 40% 
Black                               # 0 0 0 0 0 1 1 
 Serogroup by race   % 0% 0% 0% 0% 0% 100% 100% 
 Race by serogroup % 0% 0% 0% 0% 0% 33% 20% 
Am Indian/Al Native    # 0 0 0 0 0 0 0 
 Serogroup by race   % 0% 0% 0% 0% 0% 0% 0% 
 Race by serogroup % 0% 0% 0% 0% 0% 0% 0% 
Asian/Pacific Islander# 0 0 0 0 0 0 0 
 Serogroup by race   % 0% 0% 0% 0% 0% 0% 0% 
 Race by serogroup % 0% 0% 0% 0% 0% 0% 0% 
Unknown                        # 0 0 0 0 0 0 0 
 Serogroup by race   % 0% 0% 0% 0% 0% 0% 0% 
 Race by serogroup % 0% 0% 0% 0% 0% 0% 0% 
Total                               # 0 0 2 0 0 3 5 
                                       %  0% 0% 40% 0% 0% 60% 100% 
 Race by serogroup % 0% 0% 40% 0% 0% 100%   
§Others=A & W-135 
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TABLE 7-IMD in MC by Serogroup and Race/Ethnicity    
   2000-2005    
   Serogroup     
     Not   
Race/Ethnicity 
Group 
B 
Group 
C Group Y §Others Groupable Unknown Total 
White                        #   11 14 10 1 10 10 56 
 Serogroup by race   % 20% 25% 18% 2% 18% 18% 100% 
 Race by serogroup % 38% 64% 53% 25% 56% 63% 52% 
Hispanic                 # 14 7 7 3 8 3 42 
 Serogroup by race   % 33% 17% 17% 7% 19% 7% 100% 
 Race by serogroup % 48% 32% 37% 75% 44% 19% 39% 
Black                      # 1 1 2 0 0 1 5 
 Serogroup by race   % 20% 20% 40% 0% 0% 20% 100% 
 Race by serogroup % 3% 5% 11% 0% 0% 6% 5% 
Am Indian/Al Native # 2 0 0 0 0 1 3 
 Serogroup by race   % 67% 0% 0% 0% 0% 33% 100% 
 Race by serogroup % 7% 0% 0% 0% 0% 6% 3% 
Asian/Pacific Islander# 0 0 0 0 0 1 1 
 Serogroup by race   % 0% 0% 0% 0% 0% 100% 100% 
 Race by serogroup % 0% 0% 0% 0% 0% 6% 1% 
Unknown                # 1 0 0 0 0 0 1 
 Serogroup by race   % 100% 0% 0% 0% 0% 0% 100% 
 Race by serogroup % 3% 0% 0% 0% 0% 0% 1% 
Total                       # 29 22 19 4 18 16 108 
                                       %  27% 20% 18% 4% 17% 15% 100% 
 Race by serogroup % 100% 100% 100% 100% 100% 100%   
§Others=A & W-135 
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H. Invasive Meningococcal Disease (IMD) in Maricopa County(MC) by 
Month of Onset, 2000-2006 
TABLE 10- IMD in MC  by Month of Onset, 1/1/2000-6/30/2006  
    Year   
 Month of Onset                2000 2001 2002 2003 2004 2005 2006 Total 
January 6 1 4 4 1 1 2 19 
% of month total 32% 5% 21% 21% 5% 5% 11% 100% 
% of year total 21% 8% 20% 24% 9% 5% 40% 17% 
February 4 1 4 1 1 4 2 17 
% of month total 24% 6% 24% 6% 6% 24% 12% 100% 
% of year total 14% 8% 20% 6% 9% 21% 40% 15% 
March 3 4 4 2 0 4 1 18 
% of month total 17% 22% 22% 11% 0% 22% 6% 100% 
% of year total 11% 31% 20% 12% 0% 21% 20% 16% 
April 1 0 0 0 2 1 0 4 
% of month total 25% 0% 0% 0% 50% 25% 0% 100% 
% of year total 4% 0% 0% 0% 18% 5% 0% 4% 
May 0 0 0 3 1 3 0 7 
% of month total 0% 0% 0% 43% 14% 43% 0% 100% 
% of year total 0% 0% 0% 18% 9% 16% 0% 6% 
June 1 0 2 0 2 1 0 6 
% of month total 17% 0% 33% 0% 33% 17% 0% 100% 
% of year total 4% 0% 10% 0% 18% 5% 0% 5% 
July 1 0 1 0 1 1   4 
% of month total 25% 0% 25% 0% 25% 25%   100% 
% of year total 4% 0% 5% 0% 9% 5%   4% 
August 1 1 0 0 2 0   4 
% of month total 25% 25% 0% 0% 50% 0%   100% 
% of year total 4% 8% 0% 0% 18% 0%   4% 
September 2 0 0 0 0 0   2 
% of month total 100% 0% 0% 0% 0% 0%   100% 
% of year total 7% 0% 0% 0% 0% 0%   2% 
October 4 0 4 1 0 0   9 
% of month total 44% 0% 44% 11% 0% 0%   100% 
% of year total 14% 0% 20% 6% 0% 0%   8% 
November 2 4 1 4 1 2   14 
% of month total 14% 29% 7% 29% 7% 14%   100% 
% of year total 7% 31% 5% 24% 9% 11%   12% 
December 3 2 0 2 0 2   9 
% of month total 33% 22% 0% 22% 0% 22%   100% 
% of year total 11% 15% 0% 12% 0% 11%   8% 
Total 28 13 20 17 11 19 
             
*8 113 
% of total cases  25% 12% 18% 15% 10% 17%   100% 
% of year total 100% 100% 100% 100% 100% 100%   100% 
Rate 0.90 0.41 0.61 0.50 0.31 0.52 
          
*0.22   
                  
*Annualized         
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I. Invasive Meningococcal Disease(IMD) in Maricopa County(MC) by 
Serogroup, 2000-2006 
 
TABLE 11-IMD in MC by Serogroup 1/1/2000-6/30/2006  
   Serogroup    
     Not   
Year          Group B Group C Group Y §Others Groupable Unknown Total 
2000 5 1 10 2 7 3 28 
% of year 18% 4% 36% 7% 25% 11% 100% 
% of total 17% 5% 42% 50% 39% 16% 25% 
2001 8 0 3 0 2 0 13 
% of year 62% 0% 23% 0% 15% 0% 100% 
% of total 28% 0% 13% 0% 11% 0% 12% 
2002 10 6 2 1 0 1 20 
% of year 48% 29% 10% 5% 0% 5% 0% 
% of total 34% 32% 8% 25% 0% 5% 18% 
2003 2 5 2 0 6 2 17 
% of year 12% 29% 12% 0% 35% 12% 100% 
% of total 7% 26% 8% 0% 33% 11% 15% 
2004 0 2 3 0 1 5 11 
% of year 0% 18% 27% 0% 9% 45% 100% 
% of total 0% 11% 13% 0% 6% 26% 10% 
2005 4 5 2 1 2 5 19 
% of year 21% 26% 11% 5% 11% 26% 100% 
% of total 14% 26% 8% 25% 11% 26% 17% 
2006 0 0 2 0 0 3 5 
% of year 0% 0% 40% 0% 0% 60% 100% 
% of total 0% 0% 8% 0% 0% 16% 4% 
Total 29 19 24 4 18 19 113 
% of total 26% 17% 21% 4% 16% 17% 100% 
 100% 100% 100% 100% 100% 100%   
§Others=A & W-135 
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J. Invasive Meningococcal Disease(IMD) in Maricopa County(MC) Case 
Fatality Rates by Syndrome, Race/Ethnicity, Gender, Age, and 
Serogroup, 2000-2006 
 
 
 
TABLE 12- IMD in MC Case Fatality Rate by Syndrome   
  1/1/2000-6/30/2006     
    Year     
Syndrome 2000 2001 2002 2003 2004 2005 2006 Total 
Meningitis 0% 0% 10% 0% 0% 0% 20% 3% 
Bacteremia 11% 0% 5% 6% 0% 5% 20% 6% 
    Both 0% 0% 10% 0% 0% 0% 0% 2% 
Other 0% 0% 0% 0% 0% 0% 0% 0% 
Total 11% 0% 24% 6% 0% 5% 40% 11% 
 
 
 
TABLE 13- IMD in MC Case Fatality Rate by Race/Ethnicity   
 1/1/2000-6/30/2006      
   Year      
Race/Ethnicity 2000 2001 2002 2003 2004 2005 2006 Total 
White 7% 0% 10% 0% 0% 0% 20% 4% 
Hispanic 4% 0% 14% 0% 0% 0% 0% 4% 
Black 0% 0% 0% 0% 0% 5% 20% 2% 
Am Indian/Alaskan Native 0% 0% 0% 6% 0% 0% 0% 1% 
Asian/Pacific Islander 0% 0% 0% 0% 0% 0% 0% 0% 
Other 0% 0% 0% 0% 0% 0% 0% 0% 
Total 11% 0% 24% 6% 0% 5% 40% 11% 
 
 
 
TABLE 14- IMD in MC Case Fatality Rate by Gender   
  1/1/2000-6/30/2006     
    Year     
Sex 2000 2001 2002 2003 2004 2005 2006 Total 
Male 0% 0% 10% 0% 0% 5% 20% 4% 
Female 11% 0% 14% 6% 0% 0% 20% 7% 
Total 11% 0% 24% 6% 0% 5% 40% 11% 
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TABLE 15- IMD in MC Case Fatality Rate by Age    
  1/1/2000-6/30/2006     
    Year     
Age 2000 2001 2002 2003 2004 2005 2006 Total 
<1 year 0% 0% 10% 6% 0% 0% 0% 3% 
1 year 0% 0% 0% 0% 0% 0% 0% 0% 
2-4 years 4% 0% 0% 0% 0% 5% 0% 2% 
0-4 years 4% 0% 10% 6% 0% 5% 0% 4% 
5-9 years 0% 0% 0% 0% 0% 0% 0% 0% 
10-13 years 0% 0% 0% 0% 0% 0% 0% 0% 
14-17 years 0% 0% 5% 0% 0% 0% 0% 1% 
18-24 years 0% 0% 10% 0% 0% 0% 20% 3% 
10-24years 0% 0% 14% 0% 0% 0% 20% 4% 
25-64 years 0% 0% 0% 0% 0% 0% 20% 1% 
65+ years 7% 0% 0% 0% 0% 0% 0% 2% 
Total 11% 0% 24% 6% 0% 5% 40% 11% 
 
 
 
TABLE 16- IMD in MC Case Fatality Rate by Serogroup   
  1/1/2000-6/30/2006     
    Year     
Serogroup 2000 2001 2002 2003 2004 2005 2006 Total 
Group B 0% 0% 19% 0% 0% 5% 0% 4% 
Group C 0% 0% 0% 0% 0% 0% 0% 0% 
Group Y 7% 0% 0% 0% 0% 0% 20% 3% 
§Others 4% 0% 0% 0% 0% 0% 0% 1% 
Not Groupable 0% 0% 0% 0% 0% 0% 0% 0% 
Unknown 0% 0% 5% 6% 0% 0% 0% 3% 
Total 11% 0% 24% 6% 0% 5% 40% 11% 
§Others=A & W-135 
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K. Rate of Invasive Meningococcal Disease(IMD) in the US and 
Maricopa County(MC), 1983-2006 
 
  
TABLE 17-Rate of IMD in the US and MC,  
                        1983-2006  
            Cases MC          Cases US 
Year # Rate† # Rate† 
1983 17 1.02 2736 1.17 
1984 9 0.52 2746 1.16 
1985 16 0.87 2479 1.04 
1986 19 1.00 2594 1.08 
1987 20 1.00 2930 1.21 
1988 16 0.78 2964 1.21 
1989 12 0.57 2727 1.10 
1990 8 0.38 2451 0.98 
1991 16 0.73 2130 0.84 
1992 17 0.76 2134 0.84 
1993 62 2.67 2637 1.02 
1994 44 1.82 2886 1.11 
1995 45 1.78 3243 1.23 
1996 29 1.11 3437 1.30 
1997 27 1.00 3308 1.24 
1998 24 0.86 2725 1.01 
1999 32 1.12 2501 0.92 
2000 28 0.90 2256 0.80 
2001 13 0.41 2333 0.82 
2002 20 0.61 1814 0.63 
2003 17 0.50 1756 0.60 
2004 11 0.31 1361 0.46 
2005 19 0.52 1111 0.37 
2006                  *8           *0.22             N/A   
*Annualized 
†Population per 100,000, US Census estimates 
 
 
 
 
 
 
 
 
 
 63
L. Population Estimates-Maricopa County(MC) 
 
MC Population Estimates, 2000-2005, by Race/Ethnicity*    
     
Am 
Indian/ Asian/  Combined 
Year Total White Hispanic Black Al Native Pac Islander Other Group§ 
2000 3,096,692 2,053,712 759,498 110,717 49,461 71,067 36,611 267,856 
2001 3,195,893 2,083,248 814,998 115,412 52,141 75,360 38,657 281,570 
2002 3,293,441 2113578 868911 120413 53672 79791 40617 294493 
2003 3,388,711 2144584 920225 125014 55386 84109 42536 307045 
2004 3,498,587 2183362 974637 131052 57756 89519 44885 323212 
2005 3,635,528 2235502 1037514 139304 60333 97085 47731 344453 
     2000-2005 20,108,852 12,813,986 5,375,783 741,912 328,749 496,931 251,037 1,818,629 
          †2006 3,778,704        
*Source=http://www.census.gov/popest/estimates.php       
†Source=MCDPH, Office of Epidemiology      
§Combined Group=Black, Am Indian/Al Native, Asian/Pac Islander, and Other   
 
 
MC Population Estimates, 2000-2005, by Gender*  
      
Year Total Male Female   
2000 3,096,692 1,549,174 1,547,518   
2001 3,195,893 1,600,713 1,595,180   
2002 3,293,441 1651660 1641781   
2003 3,388,711 1701239 1687472   
2004 3,498,587 1758613 1739974   
2005 3,635,528 1829380 1806148   
          †2006 3,778,704     
*Source=http://www.census.gov/popest/estimates.php    
†Source=MCDPH, Office of Epidemiology   
 
 
MC Population Estimates, 2000-2005, by Age*   
       
Year Total 0-4yrs 5-9 yrs 10-24yrs 25-64yrs 65+yrs 
2000 3,096,692 244,198 239,817 667,692 1,583,864 361,121 
2001 3,195,893 260,208 250,280 690,906 1,672,191 367,308 
2002 3,293,441 270677 257466 710012 1,681,776 373510 
2003 3,388,711 280592 262102 726888 1,737,305 381824 
2004 3,498,587 290416 268677 745424 1,802,134 391936 
2005 3,635,528 298509 275582 767,403 1,890,981 403,053 
     2000-2005 20,108,852 1,644,600 1,553,924 4,308,325 10,368,251 2,278,752 
          †2006 3,778,704      
*Source=http://www.census.gov/popest/estimates.php     
†Source=MCDPH, Office of Epidemiology    
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MC Population Estimates, 1983-1999* 
     
Year Total    
1983 1,663,973    
1984 1,736,952    
1985 1,828,748    
1986 1,905,504    
1987 1,991,400    
1988 2,048,441    
1989 2,101,787    
1990 2,129,352    
1991 2,183,182    
1992 2,244,827    
1993 2,318,774    
1994 2,419,394    
1995 2,526,113    
1996 2,614,093    
1997 2,698,459    
1998 2,783,779    
1999 2,861,395    
*Source=http://www.census.gov/popest/estimates.php   
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M. US Population Estimates, 1983-2005 
 
US Population Estimates, 1983-2005* 
     
Year Total    
1983 233,791,994    
1984 235,824,902    
1985 237,923,795    
1986 240,132,887    
1987 242,288,918    
1988 244,498,982    
1989 246,819,230    
1990 249,464,396    
1991 252,153,092    
1992 255,029,699    
1993 257,782,608    
1994 260,327,021    
1995 262,803,276    
1996 265,228,572    
1997 267,783,607    
1998 270,248,003    
1999 272,690,813    
2000 282,193,477    
2001 285,107,923    
2002 287,984,799    
2003 290,850,005    
2004 293,656,842    
2005 296,410,404    
*Source=http://www.census.gov/popest/estimates.php   
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